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In December 1963 Dr. Thomas Starzl from Denver, Colorado, published 
his first three attempts of liver transplantation in humans.1 The first 
patient he described was a three year old boy with biliary atresia. He 
bled to death during the procedure. The other two patients had cirrhosis 
and a malignant liver tumor and were 48 and 67 year old males. 
Technically the liver transplant procedure was successful. However, both 
patients died of pulmonary emboli, 22 and 7½ days after the procedure.
In the decades that followed, liver transplantation evolved from an 
extremely hazardous into a standardized procedure with increasing 
survival rates and in 1983 the NIH declared liver transplantation an 
accepted therapy for end-stage liver disease.2
The first liver transplantation in the Netherlands was performed in 
1966 in Leiden University Medical Center, but due to coagulopathy the 
patient did not survive the procedure. Years later, in 1979, a successful 
liver transplant was performed in Groningen University Medical Center 
and in the years that followed liver transplant programs were also 
started in Rotterdam (1986) en Leiden (1992).
Nowadays, well over 10.000 liver transplant procedures are performed 
each year worldwide and it is the treatment of choice for acute and 
chronic liver failure. One year and five year survival rates are around 
90% and 85%, respectively.
In the early days surgical techniques and control of hemorrhage were 
of major concern. The use of cyclosporin A from 1983 on contributed 
enormously to successful immunosuppression and thus to improved 
graft and patient survival. Recently, research has shifted towards 
consequences of long-term survival, such as quality of life issues and 
recurrent disease within the liver graft. Although the outcome of 
liver transplantation has improved, the risk of serious complications 
still remains. Surgical complications, blood loss, rejection, biliary 
complications and infections all pose serious threats to the graft and its 
recipient.
The chapters 2, 3 and 7 of this thesis focus on chimerism, that is the 
coexistence of cells of different genetic origin within one organism. 
With organ transplantation, cells of two different organisms are brought 
together. Several questions arise: Do cells of recipient origin replace cells 
within the graft? Can transplanted blood stem cells develop into mature 
liver cells? Can cells of the transplanted organ be found elsewhere in the 
body? What is the clinical relevance of chimerism?
Chapters 4 and 6 focus on a fascinating group of proteolytic enzymes, 
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matrix metalloproteinases, in relation to complications after liver 
transplantation. Here questions are: Is the genetic make-up of these 
enzymes relevant? Is a different genotype of donor and recipient 
associated with the occurrence of complications like ischemia/
reperfusion injury, rejection and biliary strictures?
More everyday clinical tests are addressed in chapter 5: The value of 
routinely assessed liver enzymes and the liver ultrasound, for predicting 
biliary complications after liver transplantation is described using a time-
dependent statistical model. 
Chapter 7 addresses chimerism in liver tissue biopsies and in peripheral 
blood after liver transplantation, in those patients with a donor/acceptor 
mismatch for the studied matrix metalloproteinases.
Chimerism
Chimerism in medicine is defined as the coexistence of cells of donor 
and recipient origin within a single organism. This phenomenon was first 
described in autopsies on pregnant women who died from eclampsia, 
with fetus-derived cells in the maternal circulation.3,4 Subsequently, 
chimerism has been described frequently in pregnant women with 
fetal cells present in maternal blood.5,6 Similarly, dizygotic twins have 
shown to be chimeric for each other’s blood group.7,8 Potential sources 
for chimeric cells, other than pregnancy, are iatrogenic, namely blood 
transfusion and transplantation.9
The possible immunological consequences of chimerism are intriguing. 
Chimeric cells may be silently present, without interacting with the 
host’s immune system, e.g., resulting from pregnancy. It has also been 
hypothesized that chimeric cells may induce autoimmune disease 
by instigating loss of tolerance to self-antigens. This is supported by 
observations that chimerism is present more often in patients with 
autoimmune diseases.10-12 In transplantation medicine chimerism may 
enhance graft tolerance. 
In the early days of solid organ transplantation it has been postulated 
that cells of the recipient could replace cells in a transplanted organ and 
that this could lead to graft tolerance. Many studies have addressed 
this phenomenon with disputing and even conflicting results, and the 
relevance of chimerism in transplantation is still quite unclear. 13-16
We studied the existence of chimerism within the transplanted liver, 
looking at different lineages of non-lymphoid cells. A selection was 
made of male patients who had received a liver graft from a female 
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donor. In liver tissue biopsies cells of recipient origin were identified 
using in-situ hybridization for sex chromosomes. Findings of this study 
are described in chapter 2.
Extensive chimerism within transplanted livers can only be understood 
if circulating stem cells can develop into liver cells of mesenchymal 
phenotype. We used a different transplant model to study this. Female 
recipients were selected that had received allogeneic bone marrow 
transplantation from a male donor (for hematologic malignancies). Only 
if liver tissue was available the patients could be included in the study. 
Again, sex chromosome identification was used to identify the origin of 
cells in liver specimens, as reported in chapter 3.
If chimerism is a persisting feature after liver transplantation, one would 
expect donor-derived cells even in peripheral blood samples late after 
transplantation. The study reported in Chapter 7 not only focuses on 
chimerism in liver biopsies after transplantation, but also on chimerism in 
peripheral blood samples.
Matrix metalloproteinases and biliary complications
Matrix metalloproteinases
The matrix metalloproteinases (MMPs) are a group of proteolytic 
enzymes that are important in many physiologic processes requiring 
matrix turnover. Basement membrane and matrix components 
like collagen, elastin, gelatin and casein are major components 
cleaved and degraded by these MMPs. The breakdown of these 
components is essential for many physiological processes such as 
embryonic development, growth, reproduction, tissue resorption and 
remodelling.17-19 MMPs are also implicated in a variety of pathological 
processes such as arthritis, inflammatory bowel disease, cancer, and 
ischemic cardiovascular and neurological diseases.20-22 
Among the different MMPs, the gelatinases MMP-2 and MMP-9 are 
of particular interest in liver pathophysiology. The main cellular source 
of MMP-2 is the hepatic stellate cell, whereas the principal sources of 
MMP-9 are the leukocytes and Kupffer cells. Expression of MMP-2 is 
increased in patients with chronic liver disease.23,24 Different MMP genes 
have been shown to contain polymorphisms in their promoter region. 
These promoter polymorphisms have specific effects on the regulation of 
both MMP gene transcription and expression.
The donor liver graft is exposed to warm and cold ischemia with severe 
hypoxia before and during the transplant procedure. While ischemia 
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primes the cells for damage, the actual injury usually becomes manifest 
after the restoration of blood flow, i.e. the reperfusion. Many factors 
contribute to the extent of this ischemia-reperfusion (I/R) injury. 
Chapters 4 and 6 address the genetic MMP make-up of both donor and 
recipient, in relation to clinical complications as I/R injury, rejection and 
the development of biliary complications.
Biliary strictures
Biliary complications are a significant cause of morbidity and even graft 
loss after liver transplantation. The most common biliary complications 
are biliary leakage and biliary tract strictures.25-27 Anastomotic leakage 
occurs early after the transplantation procedure, whereas strictures occur 
later. Strictures can be divided into anastomotic and non-anastomotic.
Anastomotic strictures occur at the anastomosis of the donor common 
bile duct and the recipient common bile duct (duct to duct anastomosis) 
or of the donor common bile duct with a recipient jejunal Roux-en-Y 
limb (hepaticojejunostomy). Strictures occurring at the anastomosis are 
usually due to surgical difficulties and/or local ischemia.
Non-anastomotic strictures are thought to result from ischemia of 
the biliary epithelium by compromised arterial blood flow, hepatic 
artery thrombosis and/or ischemia/reperfusion injury. More complex 
immunologic factors and cytotoxic injury by bile salts may also 
contribute to non-anastomotic biliary strictures.28,29
We studied the relationship between MMP-2 and MMP-9 gene 
promoter polymorphisms in the donor and recipient DNA and 
the development of non-anastomotic biliary strictures after liver 
transplantation, the findings of which are described in chapter 6.
Biliary stricture formation is often insidious and typically first detected 
when biliary obstruction results in serum liver enzyme abnormalities, 
intrahepatic bile duct dilatation and/or infection. Imaging of the biliary 
tree is mandatory to make a definitive diagnosis. A cholangiography can 
be obtained endoscopically (ERCP), percutaneously (PTC) or by using 
magnetic resonance imaging (MRCP). Although ERCP and PTC are 
considered the golden standard to diagnose and treat strictures, they are 
invasive procedures. The predictive value of serum liver enzymes and 
abdominal ultrasonography for the development of non-anastomotic 
biliary strictures has been investigated before, but the results were not 
conclusive.30,31 We performed a time-dependent statistical analysis 
to assess the predictive value of serum liver enzymes and abdominal 
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ultrasound as a first step in the diagnosis of biliary strictures after liver 
transplantation (chapter 5).
A summarizing discussion of the results obtained in the different studies 
as described in the separate chapters of this thesis is given in chapter 8. 
Finally, chapter 9 provides a general discussion of the findings of this 
thesis in the Dutch language.
13
References
1.  Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. 
Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963;11:659-76.
2.  National Institutes of Health Consensus Development Conference Statement: liver 
transplantation --June 20-23, 1983 Hepatology 1984:4:107S-10S.
3.  Lapaire O, Holzgreve W, Oosterwijk JC, et al. Georg schmorl on trophoblasts in the 
maternal circulation. Placenta 2007;28:1-5.
4.  Schmorl G: Patholigisch-anatomische Untersuchungen ueber Puerperal Eklampsie. 
Leipzig, Vogel, 1893.
5.  Hamada H, Arinami T, Kubo T, et al. Fetal nucleated cells in maternal peripheral blood: 
frequency and relationship to gestational age. Hum Genet 1993:91:427-432.
6.  Lo YM, Patel P, Wainscoat JS, et al. Prenatal sex determination by DNA amplification 
from maternal peripheral blood. Lancet 1989;2:1363-1365.
7.  Booth PB, Plaut G, James JD, et al. Blood chimerism in a pair of twins. Br Med J 
1957;1:1456-1458.
8.  Nicholas JW, Jenkins WJ, Marsh WL. Human blood chimeras a study of surviving 
twins. Br Med J 1957;1:1458-1460.
9. Lee TH, Paglieroni T, Ohto H, et al. Survival of donor leukocyte subpopulations in 
immunocompetent transfusion recipients: frequent long-term microchimerism in 
severe trauma patients. Blood 1999;93:3127-3139.
10.  Nelson JL, Maternal-fetal immunology and autoimmune disease: is some autoimmune 
disease auto-alloimmune or allo-autoimmune? Arthritis Rheum 1996;39:191-194.
11.  Klintschar M, Schwaiger P, Mannweiler S, et al. Evidence of fetal microchimerism in 
Hashimoto’s thyroiditis. J Clin Endocrinol Metab 2001;86:2494-2498.
12.  Corpechot C, Barbu V, Chazouilleres O, et al. Fetal microchimerism in primary biliary 
cirrhosis. J Hepatol 2000;33:696-700.
13. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, 
chimerism, and graft acceptance. Lancet 1992;339:1579-1582.
14. Demetris AJ, Murase N, Fujisaki S, Fung JJ, Rao AS, Starzl TE. Hematolymphoid cell 
trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart 
transplantation. Transplant Proc 1993;25:3337-2244.
15. Bishop GA, Sun J, Sheil AG, McCaughan GW. High-dose/ activation-associated 
tolerance: A mechanism for allograft tolerance. Transplantation 1997;64:1377-1382.
16. Meyer D, Loffeler S, Otto C, Czub S, Gassel HJ, Timmermann W, et al. Donor-derived 
alloantigen-presenting cells persist in the liver allograft during tolerance induction. 
Transpl Int 2000; 13:12-20.
17. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological 
consequences. Curr Opin Cell Biol 1998;10:602-608.
18. Verspaget HW, Kuyvenhoven JP, Sier CF, van Hoek B. Matrix metalloproteinases in 
chronic liver disease and liver transplantation. Lendeckel U, Hooper NM, editors.
Dordrecht, the Netherlands, Springer. Proteases in Biology and Disease 5: Proteases in 
Gastrointestinal Tissues. 2006:209-234.
14
19. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu 
Rev Cell Dev Biol 2001;17:463-516.
20. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region 
of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 
1999; 99:1788-1794.
21. Kubben FJ, Sier CF, Meijer MJ, et al. Clinical impact of MMP and TIMP gene 
polymorphisms in gastric cancer. Br J Cancer. 2006;95:744-751.
22. Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, Hommes DW, 
Verspaget HW. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase 
and tumor necrosis factor-alpha single nucleotide gene polymorphisms in 
inflammatory bowel disease. World J Gastroenterol 2007;13:2960-2966.
23. Milani S, Herbst H, Schuppan D, et al. Differential expression of matrix-
metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 
1994;144:528-537.
24. Kuyvenhoven JP, van Hoek B, Blom E, et al. Assessment of the clinical significance of 
serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic 
liver diseases and hepatocellular carcinoma. Thromb Haemost 2003;89:718-725.
25. Qian YB, Liu CL, Lo CM, Fan ST. Risk factors for biliary complications after liver 
transplantation. Arch Surg 2004;139:1101-1105.
26. Rerknimitr R, Sherman S, Fogel EL, et al. Biliary tract complications after orthotopic 
liver transplantation with choledochocholedochostomy anastomosis: endoscopic 
findings and results of therapy. Gastrointest Endosc 2002;55:224- 231.
27. Turrion VS, Alvira LG, Jimenez M, et al. Management of the biliary complications 
associated with liver transplantation: 13 years of experience. Transplant Proc 
1999;31:2392-2393.
28. Guichelaar MM, Benson JT, Malinchoc M, Krom RA, Wiesner RH, Charlton MR. 
Risk factors for and clinical course of non-anastomotic biliary strictures after liver 
transplantation. Am J Transplant 2003;3:885-890.
29. Buis CI, Hoekstra H, Verdonk RC, Porte RJ. Causes and consequences of ischemic-type 
biliary lesions after liver transplantation. J Hepatobiliary Pancreat Surg 2006;13:517-
524.
30. Zoepf T, Maldonado-Lopez EJ, Hilgard P, Dechene A, Malago M, Broelsch CE et al. 
Diagnosis of biliary strictures after liver transplantation: which is the best tool? World  
J Gastroenterol 2005; 11(19):2945-2948.
31. Hussaini SH, Sheridan MB, Davies M. The predictive value of transabdominal 
ultrasonography in the diagnosis of biliary tract complications after orthotopic liver 
transplantation. Gut 1999; 45(6):900-903.
15
Chapter 2
Extensive chimerism in 
liver transplants: Vascular 
endothelium, bile duct 
epithelium, and hepatocytes










The transplanted liver has been shown to be particularly capable of 
inducing tolerance. An explanation may be the presence of chimerism. 
Cells of donor origin have been found in recipient tissues after 
transplantation of any solid organ. Evidence for the presence of cells 
of recipient origin within the transplanted liver is very limited. We 
investigated whether nonlymphoid cells of recipient origin can be found 
within human liver allografts.
Methods
Five male patients who received a liver transplant from a female donor 
and 11 patients who received an HLA-I mismatched liver transplant 
were studied. We confirmed our observations with two different 
techniques in combination with double-staining techniques. To identify 
male cells in female liver transplants, we used in situ hybridiza- tion for 
sex chromosomes. To identify specific HLA class I antigens of recipient 
origin, we used immunohistochemistry with HLA class I–specific 
antibodies. Double staining was performed to discriminate different cell 
lineages and inflammatory cells. 
Results
Endothelial cells of recipient origin were found in 14 of 16 donor livers. 
Bile duct epithelial cells of recipient origin were found in 5 of 16 cases. 
Hepatocytes of recipient origin were seen in only 1 of the 5 studied sex-
mismatched donor livers.
Conclusion
Our study provides evidence that cells of recipient origin can replace 
biliary epithelial cells, endothelial cells, and hepatocytes within the 
human liver allograft.
This is consistent with the concept that circulating pluripotent progenitor 




In the early days of solid-organ transplantation, it was postulated that 
the success of renal transplantation could be explained by the existence 
of chimerism within the graft. Especially chimerism of endothelial cells 
was thought to be relevant because endothelium is one of the major 
targets for graft rejection. Replacement of donor endothelial cells by 
recipient cells therefore would reduce the immunogenicity of the graft.1 
During the past four decades, several studies addressed the issue of 
intragraft chimerism in solid-organ transplants, with conflicting results.2-7 
Most studies did not find chimerism or found it only sporadically in 
poorly functioning grafts. Therefore, it became generally believed that 
non- lymphoid cells in organ grafts remain of donor origin. However, we 
found clear evidence of endothelial cell chimerism in renal allografts, and 
cardiac chimerism has also been described recently.8,9
The liver, in comparison to other transplanted organs, has been shown 
to be particularly capable of inducing tolerance.10-13 A number of 
hypotheses have been put forward to explain this immune-privileged 
state. One of these is the presence of chimerism.14-16 Other factors 
mentioned are regenerative capacity and the production of soluble 
major histocompatibility complex. Many studies addressed the issue 
of chimerism outside the graft resulting from donor-derived highly 
immunogenic passenger leukocytes, of which the liver is particularly rich. 
Donor-derived cells can be found in recipient peripheral tissues years 
and even decades after transplantation.14,17 The clinical relevance of the 
persistence of donor leukocyte chimerism is still unclear.18
Little is known about chimerism within the human liver allograft. Only 
few have studied this human hepatic intragraft chimerism.19,20 For 
decades, it has been the general belief that only Kupffer cells of recipient 
origin can be found within the transplant, whereas endothelial cells, bile 
duct epithelial cells, and hepatocytes remain of donor origin.19 In animal 
studies, evidence is growing that bonemarrow–derived stem cells can 
differentiate into various hepatic cell types, such as hepatocytes and 
endothelial cells.21-24 We therefore investigated whether nonlymphoid 
cells of recipient origin can be found within human liver allografts.
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Patients and Methods
Patients and Biopsy Specimens
Five male patients who received a liver transplant from a female donor 
were selected. None of the female donors had had male offspring. 
In addition, 11 patients with HLA-I mismatching allografts for A2, 
A3, A9, or A11 were studied. All patients had undergone orthotopic 
liver transplantation at Leiden University Medical Center (Leiden, The 
Netherlands) between 1993 and 1998. Liver biopsy samples were 
obtained 1 year after transplantation, according to protocol. Additional 
biopsy specimens obtained early after transplantation were studied of 
one selected patient with evidence of extensive chimerism in the 1-year 
biopsy specimen. As per protocol, a part of every biopsy specimen had 
been stored at 􏰁80°C, whereas the other part was formalin fixed and
stored in paraffin.
Approval by the Ethics Committee of Leiden University Medical Center 
was obtained.
HLA Typing
HLA typing for antigens of class I was performed using standard 
serological methods by complement-dependent microcytotoxicity on 
peripheral-blood leukocytes of recipients and splenocytes of donors, 
which are available as part of the routine pretransplantation workup.
In Situ Hybridization Sex Chromosomes
For sex-chromosome identification in the five sex-mismatched grafts, 
we performed in situ hybridization using repetitive DNA probes specific 
for X and Y chromosomes, as previously described.25 Briefly, probes 
were biotinylated by nick translation and dissolved in a 60% formamide 
hybridization mixture. Paraffin sections 6-mm thick were cut and 
mounted on poly-L-lysine–coated slides. Predigestion steps consisted of 
incubation in 1 mol/L of sodium thiocyanate solution at 80°C, followed 
by 60 to 90 minutes of treatment with 0.5% pepsin in 0.1 mol/L of 
hydrochloric acid. Hybridization was performed overnight at 42°C. 
The hybridization reaction was visualized with avidin, biotinylated goat 
antiavidin, and avidin-peroxidase developed with diaminobenzidine. 
Positive and negative controls for in situ hybridization were biopsy 
specimens from normal male and female livers.
Immunohistochemical Analysis
For HLA class I antigens, immunohistochemical staining was performed 
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on cryostat sections from the 11 HLA-I–mismatched grafts, as previously 
described.26 In short, sections were fixed in cold acetone and incubated 
with the primary antibody. Four monoclonal antibodies were used that 
recognize the HLA class I antigens A2, A3, A9, and A11 (American 
Type Culture Collection, Rockville, MD). A two-step immunoperoxidase 
technique was used with 3-amino-g-ethyl-carbazol as a coloring 
substrate. Each patient was tested with all antibodies, which provided 
many positive and negative controls. For additional negative controls, 
the second antibodies were replaced by phosphate-buffered saline. 
Recipient-derived graft-infiltrating cells stained positive for recipient 
major histocompatibility complex antigens and thus served as internal 
positive controls.
Additional Staining Techniques
For double staining, antibodies against endothelial cell–specific antigens 
(CD31, factor VIII; Dako, Carpinteria, CA) against lymphocytes, 
monocytes, and other inflammatory cells (CD45-LCA; Dako) and bile 
duct epithelial cells (keratin 18; LUMC, Leiden, The Netherlands) were 
combined with immunohistochemistry with HLA class I–specific anti- 
bodies and in situ hybridization with sex chromosomes. When possible, 
double staining was realized on the same slide. In other cases, different 
staining techniques were performed on consecutive slides.
Results
In Situ Hybridization for X and Y Chromosomes
Endothelial cells of recipient origin, i.e., Y chromosome positive, were 
found in all five sex-mismatched patients. A detail of a biopsy sample 
of a female liver transplanted into a male recipient can be seen in Figure 
1A. This detail of a vessel wall shows an endothelial cell staining positive 
with the Y chromosome probe, indicating male (recipient) origin.
Hepatocytes of recipient (male) origin were seen in only one of five 
studied patients, shown in Figure 1B. Most hepatocytes stain negative, 
indicating the donor origin of these cells, but some contain a Y 
chromosome. Hepatocytes can be tetraploid, which explains why two 
spots sometimes can be seen within one cell. Partial nuclear sampling in 
tissue sections may lead to undercounting of Y-positive nuclei.
Recipient-derived bile duct epithelial cells were seen in three of five 
patients. Figure 1C shows a biopsy sample of a female liver graft 
transplanted into a male recipient 1-year posttransplantation, showing 
a bile duct. Epithelial cells containing a Y chromosome can be seen, 
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indicating the presence of male epithelial bile duct cells of recipient 
origin. Double staining with periodic acid–Schiff (PAS) makes the bile 
duct stand out because bile duct epithelial cells are PAS negative. Figure 
1D shows the same bile duct in a consecutive slide with CD45 staining 
to confirm that the duct is free of inflammatory cells.
Immunohistochemistry for HLA Class I Antigens
A biopsy sample of an HLA-A2–negative liver graft transplanted into an 
HLA-A2–positive recipient is shown in Figure 2. A bile duct with biliary 
epithelial cells staining positive for recipient type HLA-A2 is shown in 
Figure 2A. This chimerism of bile duct epithelial cells was observed in 2 of 
these 11 HLA-mismatched patients and could be seen in smaller, as well 
as larger, bile ducts. Replacement of donor type vascular endothelium 
by recipient type could be observed to a variable degree in 9 of the 11 
studied patients. Sinusoidal endothelium staining positive for recipient-
Figure 1.
In situ hybridization for Y chromosomes.  
A female donor liver was transplanted into 
a male recipient. In situ hybridization with 
a Y-specific centromeric DNA probe was 
performed on a posttransplantation biopsy 
sample. In (A) endothelial cells of middle 
large vessels, (B) hepatocytes, and (C, D) 
bile duct epithelial cells, clear signals can 
be appreciated after in situ hybridization 
with this probe, indicating that chimerism 
has taken place in all three cell types. (C) 
A PAS background that makes the bile duct 
stand out because cholangiocytes are PAS 
negative. (D) Staining on a consecutive slide 
with CD45 and no inflammatory cells can 
be seen in or near the bile duct. The female 
donor of this graft had no male offspring. 
The presence of endogenous biotin in 
hepatocytes causes some background 




type HLA-A2 is shown in detail in Figure 2B, with double staining with 
CD31, which stains endothelial cells irrespective of their origin.
Hepatocytes were difficult to differentiate with certainty from 
inflammatory cells with this technique and therefore were not scored in 
this series.
To investigate whether chimerism can develop earlier than 1 year 
after transplantation, we studied serial liver biopsy specimens by HLA 
staining from a patient in whose graft we found extensive endothelial 
cell chimerism 1 year after transplantation. We found no evidence for 
chimerism in the biopsy sample obtained 1 week after transplantation, 
whereas it became apparent in the specimens obtained 3 months after 
transplantation.
One male HLA-A3–negative patient received an HLA-A3–positive graft 
from a female donor. In this patient, we used both in situ hybridization 
for Y chromosomes and immunohistochemistry for HLA-A3. We 
observed endothelial cell chimerism, but no bile duct epithelial cell 
chimerism, with both techniques in this patient.
Discussion
Our study provides evidence that cells of recipient origin can replace 
biliary epithelial cells, endothelial cells, and hepatocytes within the 
human liver allograft. We confirmed our observations using two 
different techniques. Additional staining techniques were performed to 
distinguish different cell lineages from inflammatory cells of recipient 
Figure 2. 
Staining with recipient-type HLA 
antibody. An HLA-A2-negative liver 
was transplanted into an HLA-A2-
positive recipient. Immunohistochemical 
staining against the HLA type of the 
recipient (HLA-A2) was performed 
on a biopsy sample obtained 1 year 
posttransplantation. (A) Bile duct epithelial 
cells stain positive for recipient type 
HLA-A2. (B) Sinusoidal endothelium staining 
positive for recipient type HLA-A2 is shown 
in red, and double staining against factor VIII 
is shown in brown. (Original magnification 
X 400.)
22
origin. Replacement of biliary duct epithelium was observed in one 
third of patients (5 of 16 patients with the two techniques combined). 
Endothelial cell chimerism was found to be very common (14 of 16 
patients). Hepatocytes of recipient origin were found in only one of five 
donor livers studied with in situ hybridization for X and Y chromosomes 
(the HLA stain is not suitable for looking at hepatocyte chimerism).
Chimerism within the human liver transplant to such extent that it 
involves endothelium, bile duct epithelium, and hepatocytes has not 
been reported previously. For decades, the general belief has been that 
lymphocytes and Kupffer cells of recipient origin are found in the liver, 
but graft bile duct epithelium, hepatocytes, and endothelium were 
considered to remain of donor origin.19,27,28
Gouw et al19 reported in 1987, with the techniques available at 
that time, that endothelium, bile duct epithelium, and hepatocytes 
remained of donor origin. However, recent reports indicate that 
replacement of donor cells by recipient-derived cells occurs much 
more frequently than was generally assumed. For instance, Gao 
et al20 found male endothelial cells in female liver graft recipients. 
Similarly, Theise et al29 reported male hepatocytes and cholangiocytes 
in female liver grafts recipients; however, Fogt et al7 recently did not 
find convincing evidence of stem-cell engraftment into transplanted 
liver tissue.
Baccarani et al30 argued that the presence of male cells in female donor 
livers can result from previous male pregnancies of the donor because 
this is a verycommon phenomenon in women with male offspring. 
To date, all published studies mentioned did not provide information 
concerning pregnancies of the donor. In the present study, we observed 
Y chromosome–positive cells in grafts from female donors without male 
offspring (G. Persijn, Eurotransplant Foundation, Leiden, The Netherlands, 
personal communication, January 2003). In a graft from which serial 
biopsy specimens were obtained, we did not find endothelial chimerism 
1 week after transplantation, whereas it was evident after 3 months. 
Furthermore, HLA antigens of the recipient are extremely unlikely to be 
identical to HLA antigens of the offspring of the donor. Our data therefore 
provide evidence that the observed endothelial cells, bile duct cells, and 
hepatocytes are of recipient origin and not derived from previous male 
pregnancies of the female donor.
In the present study, endothelial cell chimerism was much more common 
than chimerism involving bile duct epithelium. This observation is 
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consistent with the previously postulated concept that chimerism results 
from repair of damage, although other causes cannot be excluded.31
The liver is very susceptible to vascular damage and, to a lesser extent, 
bile duct damage caused by ischemia-reperfusion injury and acute 
cellular rejection.32,33 This may explain the greater percentage of 
endothelial chimerism than bile duct epithelial chimerism in the present 
study. Possibly, apoptotic or necrotic hepatocytes may be replaced 
mainly by regeneration from a local pool of donor hepatocytes.
Serious damage to biliary ducts can be observed during chronic 
ductopenic rejection. This complication, which often leads to graft 
loss, has become a rare condition and was not present in our patients. 
Although unusual, repair of bile ducts has even been reported in this 
condition.34,35 Our findings support the possibility of bile duct repair 
originating from circulating recipient precursor cells, although this does 
not exclude that it can occur next to repopulation from a local pool of 
donor oval cells.
In conclusion, our study provides evidence that recipient-derived 
cells can replace biliary epithelium, endothelium, and hepatocytes in 
liver transplants. This is consistent with the concept that circulating 
progenitor cells exist, capable of differentiating into endothelial and 
epithelial cells.21,22
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Chapter 3
Liver chimerism after 
allogeneic blood stem cell 
transplantation









Blood stem cells can mature into elements of many different lineages. 
We investigated the presence and nature of donor-derived (chimeric) 
cells within the liver after allogeneic stem cell transplantation.
Methods
Liver biopsy autopsy specimens were examined from nine female 
patients who had undergone allogeneic bone marrow (n = 6) or 
peripheral stem cell (n = 3) transplantation from a male donor. To 
identify the male origin of cells within the liver, in-situ hybridization for 
Y-chromosomes was performed in conjunction with CD45 staining to 
identify leucocytes.
Results
Hematopoietic stem cell engraftment was confirmed in all nine 
recipients. Histologic examination of the liver tissue sections revealed 
5.6-fold more Y-chromosome- positive than CD45-positive staining cells 
(P < 0.02), indicative of considerable nonleucocytic chimerism. This was 
particularly observed in patients who had developed graft-versus-host 
disease.
Conclusions
Donor-derived cells can be found in liver tissue specimens after 
allogeneic stem cell transplantation. A considerable fraction of chimeric 
(donor-derived) cells appeared to be of nonlymphohematopoietic origin. 
This finding supports the theory of blood stem cells developing into liver 
cells of mesenchymal origin.
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Introduction
Chimerism is defined in transplantation medicine as the coexistence of 
cells of donor and recipient origin. We previously described chimerism 
after transplantation of the liver and found evidence that cells of 
recipient origin can replace biliary epithelial cells, endothelial cells, 
and hepatocytes within the human liver allograft.1 This finding can be 
understood only by the existence of circulating hepatic progenitor cells. 
To study this phenomenon further we sought to evaluate liver chimerism 
after allogeneic blood stem cell transplantation.
In animal studies, abundant evidence exists that bone marrow gives rise 
to hematopoietic as well as mesenchymal stem cells. These elements can 
differentiate into various cell types within the liver, such as endothelial 
cells, hepatocytes and bile duct epithelial cells.2–7 In humans, the 
existence of circulating hepatic progenitor cells is less well established, 
although various studies seem to support the concept.8–10 Two recent 
studies found hepatocytic differentiation of recipient-derived cells 
within the transplanted liver to be a rare event.11,12 Chimerism can 
be demonstrated after sex-mismatched organ transplantation with 
the use of in-situ hybridisation for sex chromosomes. When using a 
Y-chromosome specific probe, cells of donor and recipient origin can be 
readily identified to quantitatively estimate the number of donor-derived 
cells. In combination with other staining techniques cells can be further 
differentiated.
To assess hepatic chimerism in the present study we investigated 
liver tissue specimens from female recipients of allogeneic stem cell 




From January 1994 until March 2003, we performed 100 allogeneic 
bone marrow transplants and 162 allogeneic peripheral blood stem 
cell transplantations. Female patients were selected if they received a 
sex-mismatched (male) transplant and had liver tissue available after 
transplantation. Finally, only nine female patients were included in 
this retrospective study based upon adequate available liver tissue 
specimens.
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All nine had been diagnosed with a hematologic malignancy. The 
treatment consisted of high-dose chemotherapy followed by allogeneic 
bone marrow transplantation (n = 6) or allogeneic peripheral blood stem 
cell transplantation (n = 3). All legal and ethical criteria set out by the 
ethical committee were met.
Donors
All allogeneic grafts were obtained from male, HLA-matched sibling 
donors. To obtain peripheral blood stem cells, the donors were 
pretreated with recombinant human granulocyte colony stimulating 
factor (G-CSF, dose 10 mg/kg per day SC for 4 or 5 days) and 
harvesting performed by apheresis on days 5 and 6 of G-CSF 
administration. A minimum of 4 x 106 CD34 cells/kg of recipient body 
weight was targeted for stem cell transplantation. The stem cell graft 
was T-cell depleted by adding Campath to the graft. Bone marrow was 
obtained from donors by standard methods and was harvested under 
general anesthesia.
Transplantation and Follow up
Patients were conditioned with a myeloablative regimen consisting 
mostly of cyclophosphamide at 60 mg/kg per day IV for 2 consecutive 
days followed by a single dose of total body irradiation at day 1. 
No posttransplant graft-versus-host-disease (GVHD) prophylaxis or 
hematopoietic growth factors were administered. Following incubation 
with Campath, the stem cell product was infused intravenously on  
day 0.13
After transplantation, peripheral blood, bone marrow, or both was 
collected at fixed time points for morphological examination and 
cytogenetic analysis.
Collection of Liver Tissue Specimens
Liver tissue specimens were available from all nine patients consisting  
of either needle biopsy specimens or autopsy tissue. Needle biopsy 
specimens were obtained from four patients (1, 3, 5, 9) for diagnostic 
purposes because GVHD was suspected. By the time the study began, 
six patients were deceased. In five cases, autopsy had been performed 
and liver tissue was available. From each tissue specimen, consecutive 
sections were obtained. One was used for in situ hybridization for  
the Y-chromosome in combination with an Alcian blue staining.  
A neighboring section was stained for CD45 to identify leucocytes.
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In-situ Hybridization of Y-chromosomes
For sex chromosome identification, we used in-situ hybridization using 
repetitive DNA probes specific for the Y-chromosome as previously 
described.1,14 Briefly, probes were biotinylated by nick translation 
and dissolved in a 60% formamide hybridization mix- ture. Paraffin 
sections (6 mm thick) were cut and mounted on poly-L-lysine coated 
slides. Predigestion steps consisted of incubation in 1 mol/L sodium 
thiocyanate solution at 80°C followed by 60 to 90 minutes of treatment 
with 0.5% pepsin 0.1 mol/L hydrochloric acid. Hybridization was done 
overnight at 42°C. The hybridization reaction was visualized with avidin, 
biotinylated goat-anti-avidin, and avidin-peroxidase developed with 
diaminobenzidine. Positive and negative controls for in-situ hybridization 
were tissue specimens from normal male and female livers, respectively.
Additional Staining
For consecutive staining an antibody against all known isotypes of 
the CD45 leucocyte common antigen family present on lymphocytes, 
monocytes, granulocytes, and other inflammatory cells (CD45-LCA; 
Dako, USA) was used, as described previously.1
Quantification of Y-chromosome Positive and CD45 Positive Cells
All counts were performed at a magnification of 400 and expressed 
as the mean number of positive dots or cells/high power field (HPF). 
Y-chromosome-positive cells as well as CD45-positive cells were counted 
in a median of 13 (range 8 –16) nonoverlapping fields per biopsy.
Fluorescent In-situ Hybridization Analysis on Bone Marrow and 
Peripheral Blood Samples
To determine hematopoietic stem cell engraftment, peripheral blood, 
bone marrow samples, or both were collected at fixed time points 
after transplantation. Fluorescent in situ hybridization analysis (FISH) 
was performed and the percentage of male, donor- derived nuclei was 
assessed on these samples.
Statistical Analyses
A paired nonparametric test was performed (Wilcoxon’s signed ranks 
test) to compare the results of the Y-chromosome counts with the CD45 
counts. This test was applied because a normal distribution of data was 
not expected. The differences in cell counts in relation to the presence of 
GVHD were assessed using the Kruskal-Wallis test.
P < 0.05 was considered significant.
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Results
Characteristics of Transplant Recipients
All studied recipients were females receiving stem cells from a male 
HLA-matched donor. Clinical characteristics concerning underlying 
malignant disease are outlined in Table 1. Hematopoietic stem cell 
engraftment was con- firmed in all nine patients.
Donor-derived Cells in Liver Tissue Specimens
Liver tissue was available from all studied patients. Table 2 shows the 
characteristics of the liver tissue specimens, with the histological as well as 
the clinical diagnosis. In three cases (3, 5, 9) histological evidence of GVHD 
was observed, in one other case (1) a clinical diagnosis of GVHD was made 
even though the liver tissue histology was unremarkable. Autopsy showed 
recurrent hematologic malignancy in two cases and systemic infection in 
three cases. The number of Y-chromosome positive cells/HPF is shown 
in Table 2, as well as the number of CD45 positive cells/HPF, the latter 
indicating the presence of infiltrating leukocytes (of donor origin).
No relation was observed between the FISH engraftment scores (Table 1) 
and the results from liver histology or with clinical parameters such as GVHD.
All studied liver tissue specimens showed Y-chromosome-positive 
cells, indicating male (donor) origin. Many of these were likely to be 
of hematopoietic origin, representing infiltrating leukocytes. This is 
supported by the finding of CD45-positive staining cells in adjacent 
slides (Fig 1 A and B). The absence or presence of male offspring (Table 
2) was not related to the number of Y-chromosome positive cells within 
the liver tissue. The extent of chimerism was not related to the time 
elapsed between transplantation and time of biopsy.
In some cases, donor-derived cells clearly appeared to be of 
nonlymphohematopoietic origin, supporting the presence of true tissue 
chimerism (Fig 1 C-F). Paired analysis of the median Y-chromosome and 
CD45 counts in the successive liver tissue sections revealed a statistically 
significant higher number of Y+ cells (median 19.5 vs 3.5, P < 0.02). 
Interestingly, the number of Y+ cells was particularly high in the patients 
who developed GVHD compared to those who did not (median 29.75 vs 5, 
P < 0.04), whereas the number of CD45 cells was found to not be increased 
(3 vs 4, NS). Accordingly, the Y/CD45 ratio was found to be significantly 
higher among patients who developed GVHD (7.9 vs 1.1, P < 0.02).
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Table 1. Clinical characteristics of the female allogeneic stem cell transplant recipients
Recipients Age at Diagnosis  Type of Time to Time Elapsed FISH YInterval Interval
Number Transplantation   Transplant Histology Since Last  (Bone Marrow FISH Y Bone
      Transplant* or Blood in %) Marrow-Liver
 (Years)    (Month) (Months)  (Weeks)
1 46 Acute myelogeneous Allo-BMT 14 14 98 10
  leukemia (AML)
2 49 Multiple myeloma (MM) Allo-BMT 12 12 88 5
3 29 Acute myelogenous Allo-PSCT 12 3 100 3
  leukemia
4 45 Acute myelogenous Allo-BMT 4 3 99 9
  leukemia
5 31 Chronic myelogenous Allo-BMT 3 3 99 1
  leukemia (CML)
6 39 Acute myelogenous Allo-PCST 16 16 23 6
  leukemia
7 43 Acute myelogenous Allo-BMT 10 10 NA NA
  leukemia
8 17 Chronic myelogenous Allo-BMT 3 1 99 1
  leukemia
9 58 Non-Hodgkin’s Allo-PCST 8 1 89 0
  Lymphoma (NHL)
BMT: bone marrow transplant. PSCT: peripheral blood stem cell transplantation. NA = not available.
*Last transplant: either peripheral blood stem cell transplantation (PSCT)/bone marrow transplant (BMT) or donor lymphocyte 
infusion/retransplant.
Table 2. Characteristics of the Liver Tissue Specimens of the Female Allogeneic Stem  
Cell Recipients
No Histological Out- Remarks/Cause of Death  Male Y+ Cells CD-45+ Cells Y/CD-
 Diagnosis of come* (Clinical or at Autopsy)  Offspring Median (Range) Median (Range) 45 
 Liver Specimens     per HPF per HPF Ratio
  
1 Normal ANED Clinical diagnosis of GVHD  + 19.5(11-46) 2.5 (0-7) 7.8
   Complete remission of AML
2 Normal DWED Recurrent multiple myeloma  + 23 (13-38) 13(6-35) 1.8
3 Consistent with acute GVHD DNED Histological confirmation of   35.5 (14-94) 3 (0 -12) 11.8
   chronic GVHD, DLI 3 months
   prior to liver histology
4 Congestion and cholestasis DNED Systemic candidiasis,  + 6 (1-12) 4 (1-10) 1.5
   myocardial infarction
5 Mild inflammation ANED Clinical confirmation of GVHD  24 (12-36) 3 (1-6) 8.0
   Complete remission of CML
6 Disseminated aspergillosis DNED Pneumonia, disseminated  + 3 (1-9) 3 (0 -8) 1.0
   aspergillosis
7 Normal DWED Intracranial bleed, recurrent AML + 5 (0 -11) 5 (3-9) 1.0 
8 Congestion, no recurrent DNED Merantic endocarditis, invasive  4 (0 -11) 3.5 (0-9) 1.1
 disease  aspergillosis re-PCST 1 month      
   prior to liver histology
9 Acute GVHD DWED GVHD by histology, complete  + 58 (37-90) 21 (15-65) 2.8
   remission of NHL
   DLI 1 month prior to liver histology 
*ANED = alive, no evidence of recurrent disease, DNED = deceased, no evidence of recurrent disease, DWED = deceased with evidence 
of recurrent disease. Abbreviations; GVHD: graft versus host disease, DLI: donor lymphocyte infusion, AML: acute myelogeneous 
leukemia, CML: chronic myelogenous leukemia, PSCT: peripheral blood stem cell transplantation, NHL: Non-Hodgkin’s lymphoma.
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Fig 1. 
In-situ hybridization for Y-chromosome  
(A, C, E) and parallel immunostaining for 
CD-45 common leucocyte antigen (B, 
D, F) of liver tissue sections from female 
patients receiving male bone marrow 
or blood stem cells. In several patients 
(example patient 2), most Y-positive cells 
(A, arrows) were also CD-45 positive 
(B, brown staining). In other patients 
(examples patients 1 and 5, respectively) 
many other cells (arrow heads), eg, 
hepatocytes (C and E) endothelial cells 
(E), were Y-positive and CD-45 negative 
(D and F). 
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Discussion
We identified liver chimerism by comparing the number of 
Y-chromosome-positive cells with the number of CD45-positive cells in 
consecutive thin tissue sections. Since the number of Y-chromosome-
positive cells was significantly higher than the number of CD45-staining 
cells, the presence of Y-chromosomes cannot solely be attributed to 
infiltrating leucocytes. Furthermore, (immuno)histology confirmed 
Y-positive hepatocytes and endothelial cells within the liver biopsies. 
It strongly supports the presence of nonlymphohematopoietic cells of 
donor origin within the liver emerged from mesenchymal stem cells, 
similar to what we previously described after transplantation of the 
liver.1 This indicates true chimerism within the liver. It has previously 
been postulated that male cells in females can result from male 
offspring.15,16 In our study, however, the absence or presence of male 
offspring was not related to the number of Y-chromosome-positive cells.
Studies addressing chimerism in transplantation medicine mostly rely 
on a combination of standard histologic staining techniques and in-situ 
hybridization for sex chromosomes. These techniques cannot usually be 
applied sequentially on the same tissue section because this exposes the 
tissue to rough conditions, leading to loss of quality. This is especially 
the case in autopsy material, as in our study. Therefore, consecutive thin 
tissue sections are often used, as in this study. Consecutive slides are at 
best comparable, but never identical and therefore results need to be 
interpreted with some reservation.
The existence of a hepatic progenitor cell, capable of developing into 
hepatocytes and bile duct epithelial cells, has been investigated by 
many workers.2, 9, 17-20 It has been the general belief that these hepatic 
stem cells (or ‘oval cells’) are located in the canals of Hering within the 
liver at the ductal plate. Fully differentiated hepatocytes themselves 
also possess great growth potential, and it is not known if stem cells 
are even required for hepatocyte regeneration. A recently postulated 
theory, derived from a mouse model, suggests that hepatocytes derived 
from bone marrow arise from cell fusion rather than by differentiation 
of hematopoietic stem cells.21-24 In a study of sex-mismatched liver 
transplant recipients, Ng et al12 report recipient cells constituted up to 
50% of all cells in the liver allograft. Most cells showed macrophage/
Kupffer cell differentiation, and only 1.6% showed hepatocytic 
differentiation. Again, no distinction could be made between 
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transdifferentiation and cell fusion. Körbling et al8 studied recipients of 
peripheral blood stem cells and found donor-derived hepatocytes (up to 
7%) in liver tissue specimens.
In our retrospective study, where needle biopsies were taken with 
a clinical suspicion of GVHD, it is remarkable that a high number 
of Y-chromosome positive cells was observed. One would expect 
this to result from a high number of infiltrating leucocytes, but this 
could not be confirmed because CD45 counts were not increased 
correspondingly. One could hypothesize that GVHD leads to hepatic 
tissue damage, inducing repair mechanisms,25,26 leading to the influx of 
hepatic progenitor cells from the circulation and thereby to chimerism. 
A similar response to cellular injury may be observed in solid organ 
transplantation, where different types of injury, such as ischemia/
reperfusion injury and rejection in liver transplantation, can initiate an 
immunological cascade leading to chimerism.
In conclusion, donor-derived cells may be observed in liver tissue 
specimens after allogeneic stem cell transplantation. A significant 
fraction of chimeric (donor-derived) cells appeared to be of 
nonlymphohematopoietic origin. This finding supports the theory of 
blood stem cells developing into liver cells of mesenchymal origin.
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Matrix metalloproteinases (MMPs) are involved in connective tissue 
remodeling processes associated with chronic liver disease and 
complications after orthotopic liver transplantation (OLT). Genetic 
variations in the promoter region of the MMP-2 and MMP-9 genes are 
thought to contribute not only to their transcription rate but may
also have predisposing clinical impact.
Methods
MMP-2 and MMP-9 gene promoter polymorphisms were analyzed 
in 109 patients who underwent an OLT. The relationship between 
these MMP polymorphisms in the donor and recipient DNA with the 
development of ischemia/reperfusion (I/R) injury and rejection after OLT 
was evaluated. In addition, serum MMP-2 and MMP-9 levels were
determined to illustrate potential phenotypical consequences in these 
patients.
Results
The MMP-2 and -9 genotypes of the donor and recipient or a donor/
recipient mismatch and chimerism were not associated with the 
development of late phase I/R injury or rejection in the OLT patients, 
although serological differences in the MMP levels did occur. The MMP-
2 and -9 genotype distribution did also not have a major impact on the 
respective serum levels in patients that underwent an OLT.
Conclusions
MMP-2 and MMP-9 gene polymorphisms do not seem to contribute to 
late phase I/R injury or rejection after liver transplantation. Serological 
changes in the MMP-2 and MMP-9 levels appear to occur independent 
of the MMP genotype after transplantation of the liver.
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Introduction
Matrix metalloproteinases (MMPs) comprise a large family of proteolytic 
enzymes that are important in physiological and disease-related 
extracellular matrix remodeling. The gelatinases MMP-2 and MMP-9 
are capable of digesting components of the connective tissue matrix 
and type IV collagen within basement membranes. These MMPs are 
considered to play an important role in cancer development, vascular
remodeling, fibrosis and inflammation 1,2. In recent years it has 
become evident that also in the liver MMPs are involved in diverse 
(patho)physiological processes, like fibrosis, hepatocellular carcinoma 
development and liver transplantation 3.
MMP activity is transcriptionally regulated by various factors and 
controlled by tightly regulated activation of latent pro-enzymes and 
by interaction with endogenous inhibitors such as tissue inhibitors 
of metalloproteinases (TIMPs). Recently, several single nucleotide 
polymorphisms (SNP) in the gene promoter regions of MMPs have 
been found with a functional impact on the transcription rate. The C/T 
transition at position –1306 in the promoter of MMP-2, which abolishes 
the Sp 1 binding site, and the G/A transition at position –1575, which 
is located next to an estrogen receptor binding site, leads to decreased 
mRNA transcription 4,5.
In several studies an association was demonstrated between MMP-2 
polymorphisms and the development of cancer 6,7. In the MMP-9 gene a 
SNP at position –1562 is due to a C to T substitution in the promoter 
region 8. In vitro studies have shown that this transition results in loss of 
binding of a nuclear repression protein in this region and an increase in 
transcriptional activity in macrophages. This functional effect on 
transcription was associated with the severity of coronary  
atherosclerosis 8. In accordance with the increased activity of the –1562 
T allele this allele was found to be associated with elevated MMP-9 
plasma levels in patients with cardiovascular disease 9.
In the liver, the hepatic stellate cell is suggested to be the main cellular 
source of MMP-2. Liver fibrosis is a dynamic process in which activated 
stellate cells are involved in the synthesis of matrix proteins and in the 
regulation of matrix degradation. Increased mRNA expression of 
MMP-2 was reported in liver biopsy samples of patients with cirrhosis 10. 
In addition, serum levels of MMP-2 are found to be increased in patients 
with chronic liver disease and to correlate with the severity of the liver 
function impairment 11. MMP-9 is released predominantly from 
neutrophils and macrophages, but the principal source in the liver is 
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thought to be the Kupffer cell, the resident macrophage of the liver 12. 
MMP-2 and MMP-9 are presumed to play a critical role in cold storage 
injury during preservation and in the subsequent reperfusion injury of 
liver grafts 13. The extracellular matrix may also be an important target in 
the process of acute rejection after orthotopic liver transplantation 
(OLT). In a previous study we demonstrated elevated
serum levels of MMP-9 at 1 week after OLT in patients with acute 
allograft rejection 14.
The aim of the present study was to establish the relationship between 
MMP-2 and MMP-9 gene promoter polymorphisms in the donor 
and recipient DNA and the respective MMP serum levels with the 




Our study group consisted of 109 patients who underwent an OLT. 
All blood and tissue samples from these patients were collected 
prospectively and retrospectively analysed. Longitudinal MMP serum 
levels were measured in a representative subset of 27 patients. MMP 
genotype distribution in this subset was similar to the study group of 
109 patients. Serum samples for MMP measurement were collected
at 7 time points: before transplantation (I) and at 2 days (II), 1 week 
(III), 1 month (IV), 3 months (V), 6 months (VI) and 1 year (VII) after 
OLT. Serum samples were stored at –70 °C until use. MMP-2 and  
MMP-9 concentrations were determined using highly specific enzyme-
linked immunosorbent assays, which measure the pro-enzyme, active- 
and inhibitor complexed forms, as described previously 15,16.
Ischemia and Reperfusion Injury
The degree of late phase hepatocellular injury was evaluated by 
measurement of aspartate aminotransferase (AST) during the first week 
after OLT. Patients were classified into 2 groups depending on whether 
the serum AST peak was lower than 1,500 IU/L (no or mild I/R injury) 
or higher than 1,500 IU/L (more severe I/R injury), respectively 17,18.
Rejection
Liver biopsies were taken according to our protocol at approximately 
1 week after OLT or when there was a suspicion of rejection. Acute 
allograft rejection was graded according to the Banff scheme and the 
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histopathological severity was evaluated by three specific features 
(portal inflammation, bile duct inflammation/damage, venous 
endothelial inflammation) 19. In this study patients were divided into 2
groups according to the presence or absence of acute allograft rejection 
at approximately 1 week. The rejection had to be clinically relevant, i.e. 
histologically confirmed and treated with additional immunosuppression.
Determination of SNPs of the MMPs 
Genomic DNA was extracted by routine methods from peripheral blood 
leukocytes. In addition, DNA samples from the blood of the liver donor 
were obtained from the Eurotransplant Reference Laboratory and DNA 
was isolated from liver biopsy tissue of the allograft in the recipients 
obtainedmseveral months (median 17, range 5 to 48) after OLT.
The –1306 C/T MMP-2 gene promoter polymorphism was determined 
by tetra-primer amplification refractory mutation system- polymerase 
chain reaction (PCR) analysis, the principles of which are described 
elsewhere 20,21, and confirmed by direct sequence analysis of 4 patients. 
Briefly, the region flanking the SNP was amplified with outer primers 
5’-ACCAGACAAGCCTGAACTTGTCTGA-3’ and 5’- 
TGTGACAACCGTCTCTGAGGAATG-3’ together with inner allelic 
specific primers 5’-ATATTCCCCACCCAGCACGCT- 3’ and 
5’-GCTGAGACCTGAAGAGCTAAAGAGTTG- 3’. Genotypes CC, CT and 
TT (542+379; 542+379+ 211; 542+211 bp, respectively) are easily 
identified from the migration pattern on agarose gels. The other gene 
promoter polymorphisms were determined as described previously 20,22. 
In brief: transition polymorphism G/A at –1575 of the MMP-2 promoter 
gene was determined by PCR amplification using outer primers also 
used for the –1306 polymorphism followed by restriction enzyme 
fragment length (RFLP) analysis with BspH I to produce 542, 
542+458+83 or 458+83 bp fragments indicating the GG, GA and AA
genotype, respectively. The SNP C/T at position –1562 of the MMP-9 
gene promoter was determined by PCR-RFLP. The SNP flanking region 
was amplified using primers 5’- ATGGCTCATGCCCGTAATC-3’ and 
5’-TCACCTTCTTCAAAGCCCTATT- 3’ followed by restriction analysis 
with Sph I to produce 352, 352+207+145 or 207+145 bp fragments
in case of CC, CT and TT genotype, respectively.
Statistical Analysis
Genotype frequencies were analyzed by generating two-by-two 
contingency tables and statistical analysis was performed using the 
Chi-square test or Fischer’s Exact test, when appropriate, using SPSS 
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software (SPSS Inc; Chicago, IL, USA). Differences in MMP levels 
according to the genotype and disease complications were assessed 
by the Mann-Whitney U or the Wilcoxon signed ranks test for 
nonparametric data 14,23. MMP levels are expressed as mean ± S.E.M. 
Differences were considered to be significant at P-values of <_0.05.
Results
Patients
Our study group consisted of 109 patients (70 male) who underwent 
an OLT. The median age was 47 years (range 16 to 67). 30 patients 
had chronic viral hepatitis, 26 patients had cholestatic liver disease, 
21 patients had alcohol-related liver disease, and a miscellaneous 
group (n=32) was included, consisting of 7 patients with autoimmune 
hepatitis, 9 with cryptogenic liver cirrhosis, 4 with neoplastic disorders,  
2 with azathioprine induced liver cirrhosis, 2 with polycystic liver disease, 
1 with acute fatty liver of pregnancy, 4 with Budd Chiari Syndrome, two 
patients with Wilson’s disease and one patient with alpha-1 antitrypsin 
deficiency.
The Role of MMP Polymorphisms in Liver Transplantation
The frequencies of the donor and recipient MMP-2 and MMP-9 
genotypes in relation to the development of IR-injury and rejection after 
OLT are shown in Table 1. Because the gene polymorphisms at the 
-1306 and the -1575 position of the MMP-2 promoter were found to 
be in complete linkage disequilibrium only the data at the -1306 position 
are given. Late phase I/R injury was graded “more severe” in 33 of 109 
patients after OLT, and rejection had occurred in 20 patients. The 
genotype frequencies for MMP-9 determined in the donor and recipient 
DNA of patients with or without late phase I/R injury, and with or 
without rejection, however, were not significantly different (Table 1A). 
Also, the MMP-2 genotype frequency of the donor and recipient were 
not significantly different according to the development of I/R injury or 
rejection, although the donors were found the have a significantly 
different genotype frequency distribution from the recipients (Table 1B). 
Therefore, we assessed the clinical impact of such a mismatch in allelic 
composition at the MMP-2 and MMP-9 SNP loci between the donor 
and recipient. However, no statistically significant differences between 
the presence or absence of a mismatch at –1306 C/T MMP-2 or –1562 
C/T MMP-9 were found in relation to the development of I/R injury and 
to rejection after liver transplantation (Table 2). Obviously, due to the 
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Table 1. The Development of IR-Injury and Rejection after OLT Stratified According to 












































X2 = 0.1; P = 0.70 X2 = 0.2; P = 0.66
80 (73.4) 29 (26.6) 83 (76.1) 26 (23.9)











































X2 = 1.2; P = 0.28 X2 = 0.7; P = 0.40
50 (45.9) 59 (54.1) 74 (67.9) 35 (32.1)
X2 = 9.9; P = 0.002
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donor-recipient differences, the frequency of a mismatch in MMP-2 was 
significantly higher than in MMP-9 (57.8% versus 33.9%, Table 2). 
Serum levels of MMP-2 are increased in patients with chronic liver 
disease and therefore a drop of MMP-2 levels was expected after  
OLT 11. This decrease indeed was seen, as shown in Fig. (1), but 
occurred independent of the genotype. Serum levels of MMP-9 peak at 
1 week after OLT, which is associated with acute allograft rejection, as 
previously reported 14. Irrespective of a genotype mismatch between the 
donor and the recipient, we found a comparable serum MMP-9 peak 
and pattern over time (Fig. 1). In some patients with a mismatch 
evidence of chimerism was demonstrated in the DNA samples from the 
liver biopsy tissue of the allograft. The chimerism was identified by the 
presence of an MMP SNP signal from the recipient in addition to the 
strong signal of the donor in the DNA from the allograft liver biopsy 
(Fig. 2). These chimerisms were demonstrated in 37.5% of patients with 
a MMP-9mismatch and in 62.5% of patients with a MMP-2 mismatch, 
but were of no additional clinical significance.
Discussion
Our study shows that the –1306 C/T MMP-2 and the – 1562 C/T 
MMP-9 gene promoter polymorphisms, determined in the donor and 
the recipient, are not associated with rejection or late phase I/R injury 
after OLT. Moreover, the consistent changes in the serum MMP-2 and 
MMP-9 levels after OLT evolve independent of the genotypes and 
donorrecipient mismatches.  
Table 2. The Development of IR-Injury and Rejection after OLT Stratified According to the 



































X2 = 0.5; P = 0.47 X2 = 0.2; P = 0.68
46 (42.2) 63 (57.8) 72 (66.1) 37 (33.9)
X2 = 11.5; P = 0.001









•: Patients without a mismatch between donor and recipient; : Patients with a mismatch.
* MMP-2: P<0.01 for both groups compared to time point I, • two outliers.
* MMP-9: P<0.02 time point III compared to time point I, for both groups.
Fig. 2. 
MMP genotype chimerism, indicated by 
genotypes between brackets, in OLT allografts 
based on the SNP analysis of the MMP-2 –1306 
C/T locus and the MMP-9 –1562 C/T locus of 
sets of DNA from the transplanted liver (Li) and 
blood leukocytes of the recipient (R) and from 
blood leukocytes of the donor (D).
Fig. 1. 
MMP-2 en MMP-9 serum concentrations before 
transplantation (I) and at 2 days (II), 1 week (III), 
1 month (IV), 3 months (V), 6 months (VI) and 1 
year (VII) after OLT. Data are expressed as mean 
± SEM.
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Polymorphisms in the promoter region of a number of MMP genes have 
been shown to influence MMP gene expression and/or were found to 
be associated with susceptibility of disease like coronary atherosclerosis, 
aneurysms, and cancer 24. For example, a functional SNP in the promoter 
of the MMP-2 gene (–1306 C/T) leads to a diminished promoter activity 
and is principally studied in cancer [5]. In case-control studies from 
China it was demonstrated that the –1306 CC MMP-2 genotype may 
constitute a common susceptibility factor for cancer of the  
breast, lung, and stomach, whereas in hepatocellular carcinoma it was 
not 6,7,25,26. Liver fibrosis is a highly dynamic process in which multiple 
genes may interact with environmental factors. Polymorphisms in genes 
encoding immunoregulatory proteins, proinflammatory cytokines, and 
fibrinogenic factors may influence disease progression 27. MMPs play 
an important role in remodeling of the hepatic extracellular matrix and 
increased expression of MMP-2 was found in human liver fibrosis 10,28. 
However, studies on MMP-2 promoter polymorphisms have never been 
reported in patients with chronic liver disease. In the present study 
the serum MMP-2 levels in patients with diverse chronic liver disease 
were increased pre-OLT and decreased significantly over time after 
OLT but unrelated to the –1306 C/T MMP-2 genotype and donor-
recipient mismatch. Apparently, MMP-2 expression changes in liver 
disease processes and may even be indicative for disease progression, 
as reported for hepatic fibrosis 29 and recurrence of hepatocellular 
carcinoma 30, but this may occur unrelated to the genotypic constitution. 
Other studies similarly demonstrated that disease related changes in 
the hepatic mRNA MMP-3 expression was determined by the MMP-3 
(–1171 5A/6A) promoter polymorphism, while the genotype distribution 
was not significantly different between controls, patients with chronic 
hepatitis, and patients with cirrhosis 31,32.
The expression of MMP-9 is regulated primarily at the transcription level 
in response to different regulators such as interleukin-1, tumor necrosis 
factor-alpha, and epidermal growth factor 2. The functionally most 
important SNP at position –1562 in the MMP-9 gene leads to increased 
transcriptional activity in individuals with the T allele and is
associated with severity of coronary atherosclerosis 8. In another study, 
the T allele of the –1562 C/T polymorphism was associated with 
elevated MMP-9 serum levels, but no association with cardiovascular 
mortality was found 9. Studies on functional polymorphisms of MMP-9 
in patients with pulmonary emphysema 33, abdominal aneurysm 34, end-
stage renal disease 35, multiple sclerosis 36, and intracranial aneurysms 
revealed contradictory results 37,38, In liver disease it has become obvious 
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that MMP-9 may have a very important impact, as illustrated by the 
predictive value for recurrence of hepatocellular carcinoma after liver 
transplantation 30, the protection against hepatic I/R injury in MMP-9 
deficient/neutralized mice 39,40 and a contribution to the progression 
of chronic liver disease 41. We found a peak in serum MMP-9 levels at 
1 week after OLT in patients with rejection. The MMP-9 is most likely 
derived from infiltrating neutrophils in the portal triad of the liver or 
from Kuppfer cells activated by cytokines from the infiltrating cells 14. 
However, the serological changes in MMP-9 were found to be unrelated 
to the –1562 C/T MMP-9 gene promoter polymorphism of the patients, 
donors and the presence of mismatch.
In previous studies we demonstrated that MMP-9, but not MMP-2, 
could play an important role in immediate I/R injury 23 and in acute 
allograft rejection after liver transplantation 14. In the present study we 
assessed the impact of the donor MMP genotypes on the outcome and 
complications after liver transplantation but no associations were
found. We did observe significant differences in the MMP-2 genotype 
distribution between donors and recipients but not in relation to clinical 
complications as I/R and rejection after OLT. Also the presence of a 
mismatch in the MMP genotype between the donor and the recipient 
and the evidence of chimerism in the liver biopsy tissue of the allograft 
were found not to contribute to the clinical complications after
transplantation. The development of the chimerism we observed might 
in part be explained by the presence of lymphocytes and Kupffer cells 
of recipient origin, but recently it was demonstrated that recipient-
derived cells can also replace biliary epithelium, endothelium, and even 
hepatocytes in liver transplants 42.
In conclusion, this study indicates that MMP-2 and MMP- 9 gene 
promoter polymorphisms are not associated with late phase I/R injury 
or rejection after liver transplantation. Furthermore, functionally 
and clinically relevant changes in the serum levels of MMP-2 and 
MMP-9 in patients who underwent OLT develop independent of the 
MMP promoter genotype. Although MMPs are involved in both the 
progression and resolution of disease processes in the liver 43, the exact 
contribution of the MMP genes still has to be elucidated.
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After orthotopic liver transplantation (OLT) early detection of biliary 
strictures is important. Our aim was to evaluate the predictive value 
of routine serum liver chemistry profiling and abdominal ultrasound as 
non-invasive diagnostic tools in detecting biliary strictures after OLT.
Methods
We performed a retrospective study in which 141 OLTs, performed 
between 1992 and 2007 with more than 1 year follow-up, were 
included. Routinely assessed serum levels of alkaline phosphatase, 
alanine-aminotransferase, aspartate-aminotransferase, gamma-glutamyl 
transpeptidase and bilirubin at 3, 6, 9 and 12 months, and abdominal 
ultrasounds performed at 3, 6 and 12 months after OLT were evaluated. 
Time-dependent Cox regression analysis was performed to identify 
predictive factors for the development of biliary strictures.
Results
Eighteen grafts developed non-anastomotic strictures (12.8%) and 18 
grafts (12.8%) developed anastomotic strictures requiring intervention. 
An elevated gamma-glutamyl transpeptidase (HR 1.25 per 100 IU/L;  
p = 0.04) and dilated bile ducts on ultrasound (HR 3.54; p < 0.01) were 
found to have an independent predictive value for the development of 
biliary strictures requiring intervention. Bilirubin and the other studied 
liver enzymes were not independently predictive.
Conclusion
Dilated bile ducts on ultrasound and elevated gamma-
glutamyltranspeptidase after OLT are independent predictive factors for 
the development of biliary strictures requiring intervention. 
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Introduction
Biliary complications are common after orthotopic liver transplantation 
(OLT), with a reported prevalence of 6% to 35%.1-4 Biliary strictures 
occurring at the surgical anastomosis are classified as anastomotic 
strictures (AS), whereas strictures in the donor biliary tree are referred 
to as non-anastomotic strictures (NAS). Stricture formation is often 
insidious and usually only then detected when lead to clinical symptoms 
as cholestasis, with serum liver enzyme abnormalities, intrahepatic 
bile duct dilatation and/or infection.5 The definite diagnosis is made 
with endoscopic retrograde cholangiopancreatography (ERCP), 
percutaneous transhepatic cholangiography (PTC) or by magnetic 
resonance cholangiopancreatography (MRCP).6,7 Although ERCP and 
PTC are considered the gold standard, they are invasive procedures 
and associated with considerable morbidity. ERCP and PTC are often 
immediately performed when clinical symptoms such as jaundice or 
cholangitis are present.8 Several uncontrolled series evaluated the 
efficacy of ERCP in predicting biliary complications.8,9 Most of these 
were evaluated in settings where patients present themselves with 
symptoms such as cholangitis due to a biliary stricture. However, 
in many liver transplant programs liver chemistry and enzymes and 
abdominal ultrasound are routinely assessed in an outpatient clinic at 
certain intervals as a screening tool, often long before patients develop 
symptoms such as fever or abdominal pain. It is remarkable that only 
few studies addressed the predictive value of routinely assessed serum 
liver chemistry profiles and abdominal ultrasonography (US) after OLT 
as predictors for the occurrence of biliary strictures.10 Although some 
studies did evaluate the prognostic value of liver chemistry and US, the 
usefulness of routinely assessing these diagnostic tools in clinical setting 
remains unclear in a post-transplantation population.10,11 The risk of 
developing biliary strictures varies over time, probably in association 
with the liver chemistry profile and US findings. The aim of the present 
study was to evaluate the predictive value of routinely assessed serum 
liver chemistry and abdominal ultrasound as non-invasive predictors for 
the development of biliary strictures requiring intervention after OLT.
Patients and Methods
Patients
We examined 141 consecutive OLTs with at least one year of follow-up 
and complete data on serum liver chemistry and enzymes and upper 
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abdominal ultrasonography (US) performed between September 1992 
and April 2007 performed at the Leiden University Medical Centre. 
Re-transplantations (n=31) were excluded. Clinical data were obtained 
from the medical digital records, the hepatological and surgical patient 
charts, and endoscopy reports. Follow-up was up to August 2008 with a 
median of 5.2 years (range 1.0 -15.6). 
OLT was performed according to standard procedures with cavo-caval, 
porto-portal, and hepatic artery to hepatic artery anastomosis. A duct-
to-duct biliary anastomosis over an 8-12 Ch stent was performed, if 
possible. The biliary stent was removed after 6 weeks or removed earlier 
as indicated. In some cases the hepatic artery was anastomosed to 
the aorta via an iliac conduit. All patients received immunosuppressive 
agents according to protocol: cyclosporin A or tacrolimus, prednisone 
during the first half-year and patients with renal impairment received 
azathioprine before 2001 or mycophenolate mofetil from 2001 on. From 
2001 on, basiliximab was given post OLT. In some cases sirolimus was 
used after month 3 in which case the calcineurin-inhibitor was lowered 
or discontinued. All patients received ursodeoxycholic acid in the first 3 
months after transplantation. 
Biochemical variables
Serum liver enzymes levels of alkaline phosphatase (ALP), alanine-
aminotransferase (ALAT), aspartate-aminotransferase (ASAT) and 
gamma-glutamyltranspeptidase (GGT) were determined daily during the 
first two weeks and weekly for two months, after that at 3, 6, 9, and 
12 months post-operatively. The same was done for bilirubin.  Only the 
latter 4 time points were included in the study because in the first three 
months after liver transplantation liver enzymes are very susceptible to 
change due to procedure-related causes such as ischemia-reperfusion 
damage, rejection and infections. Therefore, the first three months 
of liver chemistry assessments, ultrasounds and biliary strictures after 
transplantation were excluded.
The upper limit of normal serum level was for ALP 120 IU/L, for ASAT, 
ALAT and GGT the upper limits of normal were 40 IU/L, 40 IU/L and 51 
IU/L, respectively. The upper limit for bilirubin (total) was 17 μmol/L. 
Imaging variables
US was performed routinely on day 0, 1 and 7, and subsequently at 3, 6 
and 12 months after OLT. The US performed at 3, 6 and 12 months were 
included in this study. These US were performed by different experienced 
radiologists. A bile duct of >7 mm on ultrasound was considered dilated 
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and prompted either direct intervention by ERCP or PTC or additional 
MRCP which in turn might prompt ERCP or PTC.  Routine abdominal CT 
scan was performed after 3 to 7 days post-OLT and routine liver biopsies 
were performed at 6 months after transplantation. Additional liver 
biopsies were taken on indication. Virology monitoring, including CMV-
DNA, was performed frequently in the first year. 
Clinical variables
Presentation of a biliary stricture (anastomotic and non-anastomotic) 
was with clinical symptoms such as cholangitis, pruritus or jaundice and/
or abnormal liver chemistry. Diagnostic tests to confirm the diagnosis 
were performed on indication but not included in the present analyses. 
Only strictures occurring more than three months after OLT that 
required intervention by ERCP, PTC or surgery were included in this 
study. From 2001 on, routine ERCP with stent-removal was performed 
at week 6 post-OLT in case of a duct-to-duct anastomosis. Strictures 
were treated endoscopically with ERCP and dilation and/or stenting, 
and percutaneously with percutaneous transhepatic cholangiodrainage 
(PTCD) or with surgical intervention.
Statistical analyses
We have used a time-dependent Cox regression model to evaluate 
the diagnostic value of liver enzymes and routine US assessments in 
predicting biliary strictures. The Cox proportional-hazards regression 
model for time-to-event data (in this case the development of biliary 
strictures) takes into account the changes of variables over time, in this 
study changes of liver enzymes and bile duct dilatation on US. Time 
dependent predictors (covariates) for stricture development in this study 
were liver chemistry variables ALP, GGT, ASAT, ALAT and bilirubin, 
obtained with an interval of three months at 3, 6, 9 and 12 months 
post OLT and US performed 3, 6 and 12 months post OLT. Recipient 
characteristics, variables on etiology of liver disease and procedure-
related variables were baseline characteristics. Coefficients were 
considered significant when p<0.05. The reported hazard ratios and 
p-values are per 100 international unit elevation for the liver enzymes. 
Bilirubin levels are reported per 10 μmol/L elevation.
Ethical committee
All data were obtained as part of patient care according to a strict 
protocol after OLT. There was permission from the local ethics 
committee to use these data. 
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Results
Patients and biliary strictures
Baseline characteristics of recipients, etiology of liver disease and 
procedure-related variables are presented in Table 1. Non-anastomotic 
biliary strictures requiring intervention developed in 18 of the 141 grafts 
(12.8%). Median time from OLT to NAS was 8.5 months (range 3-29). 
Median follow-up after the diagnosis of NAS was 5.5 years (range 0.0 – 
11.6). Anastomotic strictures developed in 18 out of 141 grafts (12.8%). 
Median time from OLT to AS was 5.5 months (range 3-72). Median 
follow-up after the diagnosis of an anastomotic stricture was 2.8 years 
(range 0.6-15.3). A total of twenty-one ERCPs and twelve PTCs for the 
management of strictures were performed in the included cases. In three 
cases a surgical intervention to resolve the stricture was necessary. There 
was no difference between the duct-to-duct type anastomosis and the 
Roux-en-Y anastomosis in the occurrence of biliary strictures (p = 0.88). 
Other potential risk factors were calculated and are listed in Table 2.   
Liver chemistry and abdominal ultrasound
Elevation of serum liver enzymes ALP, GGT, ASAT and ALAT above the 
upper limit of normal occurred in respectively 57.4%, 71.6%, 53.9%, 
and 61.0% of the patients at 3, 6, 9 or 12 months after OLT. Bilirubin 
was elevated in 41.6% of the cases. There was a significant relationship 
between the level of GGT and the development of biliary strictures 
requiring intervention, both in the univariate and in the multivariate 
analysis (hazard ratios 1.35 and 1.25, p < 0.001 and p = 0.04, 
respectively), as presented in Tables 2 and 3. AF above the upper limit of 
normal was also found to be a significant indicator for the development 
of biliary strictures in the univariate analysis (p < 0.001), but not in the 
multivariate analysis (p = 0.23). Elevated ALAT and ASAT were not 
associated with biliary strictures in both univariate and multivariate 
analyses (ALAT; p = 0.61. and p = 0.81 respectively, ASAT; p = 0.62 
and p = 0.42 respectively). Elevation of bilirubin was not significant 
in both univariate and multivariate analysis for the prediction of the 
development of biliary strictures (p = 0.08 and p = 0.33 respectively 
(Table 3) Regarding the US assessments a significant relationship was 
found between dilated bile ducts on abdominal ultrasound and the 
successive development of a biliary stricture requiring intervention in 
both the univariate (hazard ratio = 4.48, p < 0.001) and multivariate 
analysis (hazard ratio = 3.54, p < 0.01). (Table 3)
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Table 1. Baseline characteristics of 141 orthotopic liver transplants.
Recipient data
- Male/ Female      91/50
- Median age (years) (range)     50 (16 – 70)
Etiology of liver disease
Hepatitis B/C cirrhosis      10/22
Biliary cirrhosis (PSC/PBC)     30 (22/8)
Alcoholic cirrhosis      25
Hepatocellular carcinoma     19
Other       35
Donor and OLT procedure data
DBD / DCD donor      135/6
Choledochocholedochostomy (duct-to-duct)/ Roux-en-Y hepaticojejunostomy 132/9
Donor warm ischemic time (DCD donors) (minutes) (range)   17 (11 – 23)
Cold ischemic time (minutes) (range)    605 (268 – 1095)
Recipient warm ischemic time (minutes) (range)    35 (16-90)
Table 2. 
Univariate analysis of potential predictors for the development of biliary strictures (BS).
Time-dependent analysis was used to calculate the  predictive value of routinely performed  liver 
chemistry profile assessments  and dilated bile ducts on abdominal ultrasound (US)  for detecting BS 
requiring intervention after OLT (n=141). The hazard ratios for liver enzymes are shown per 100 IU/L 
increase. The hazard ratio for bilirubine is shown per 10 μmol/L increase.
  
Clinical Variables   Hazard Ratio (95% CI)  P-Value
Dilated bile ducts on US  4.48 (1.97 -10.12)  < 0.001 
GGT    1.35 (1.22 - 1.49)  < 0.001
ALP    1.55 (1.22 -1.89)  < 0.001
ALAT    1.13 (0.74-1.82)  0.61
ASAT    1.19 (0.61 -2.45)  0.62
Bilirubin    1.07 (0.99 – 1.16)  0.08
Gender    0.64   0.23
Type of surgical anastomosis  
(duct-to-duct / Roux-en-Y)  0.90   0.88
Age (at OLT)   0.98   0.14
Table 3. 
Multivariate time-dependent Cox regression analysis for liver enzymes and dilated bile ducts on 
abdominal ultrasound (US) for detecting presence of BS requiring intervention after OLT (n=141). 
Gamma-glutamyltranspeptidase (GGT) and US remain significant predictors for the development of 
BS. The Hazard ratio for GGT shows the risk of having a stricture with each 100 1U/l increase.  
The hazard ratio for bilirubin was calculated for each 10 μmol/L increase.
 
  
Clinical Variables   Hazard Ratio (95% CI)  P- value
Dilated bile ducts on US  3.54 (1.47 – 8.49)  < 0.01
GGT    1.25 (1.02 – 1.55)  0.04
ALP    1.46 (0.93 – 2.24)  0.10
ALAT    0.92 (0.46 – 1.85)  0.81
ASAT    0.55 (0.13 – 2.33)  0.42
Bilirubin    0.99 (0.80 – 1.08)  0.33
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Discussion
Biliary strictures frequently complicate orthotopic liver transplantation 
and lead to significant morbidity, graft loss and mortality. Early diagnosis 
and prompt intervention is therefore of great clinical importance. 
Cholangiography remains the most sensitive and specific assessment in 
diagnosing biliary strictures but is invasive. The most commonly used 
and least invasive diagnostic modalities after OLT are routine serum liver 
chemistry profile determinations and abdominal ultrasound. Surprisingly, 
there are only few studies on the prognostic value of these routinely 
performed laboratory tests and ultrasound. Our aim was to evaluate 
the predictive value of these routine diagnostic tests, often performed 
in an outpatient clinic setting, for the development of clinically relevant 
biliary strictures in a time-dependent model. NAS and AS represent 
different entities and have different etiologies.  However, the tools for 
diagnosing and treating NAS and AS are generally similar. Therefore, in 
our study, these data were pooled. We found that after OLT an elevated 
serum gamma-glutamyltranspeptidase level and bile duct dilatation 
on abdominal ultrasound are independently highly predictive for 
development of biliary strictures requiring intervention. 
The current findings are in accordance with non-transplantation studies 
in which GGT corresponds with the presence of biliary strictures, while 
mixed data are reported on the predictive value of liver chemistry and 
ultrasound for the presence of biliary complications after OLT.8,10,12,18 
Some studies showed no relationship between an aberrant serum liver 
chemistry profile and biliary complications post-OLT, whereas other 
studies did.5,7,10,11,18 
Abdominal ultrasound is a non-invasive, readily available and economic 
diagnostic tool. However, several studies observed that ultrasound 
is not very sensitive in detecting biliary strictures in a post transplant 
population, in contrast to a non-transplant population, whereas few 
studies reported the opposite.3,8,11,13 We found bile duct dilatation 
on abdominal ultrasound to be a powerful predictor of subsequent 
development of biliary strictures requiring therapy, exemplified by 
the high hazard ratio of 3.54 in the multivariate analysis. The use of 
abdominal ultrasound remains one of the safest and cheapest diagnostic 
tools for early detection of biliary strictures.
Although it may be not as sensitive as MRCP, these data show that 
dilated bile ducts on US after OLT often precedes biliary strictures 
requiring intervention. Sensitivity may be even better if strictures are 
clinically suspected. Dilated bile ducts on abdominal US after OLT 
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should prompt cholangiography. Whether this should be a MRCP first or 
immediate ERCP or PTC is a matter of debate: With ERCP and PTC the 
contrast flow across the stenosis can be assessed dynamically (and the 
use of an air-inflated balloon can be of additional value). MRCP is more 
expensive than US and access to MRCP is often more difficult. Quick 
action is warranted to prevent cholangitis in the immunosuppressed 
patient. MRCP can be considered first if there is less urgency. 
Apart from a dilated bile duct on ultrasound there was an independent 
association between the increased serum level of gamma-
glutamytranspeptidase and the risk of a biliary stricture requiring 
intervention. The accompanying hazard ratio (HR=1.25) is given per 100 
units increase of GGT above the upper limit of normal (i.e., 151 U/L). To 
put these figures in the appropriate perspective: a GGT of 151 U/l (100 
U/l above normal range) would result in a 25% increased risk of having 
a stricture requiring therapy. In fact, the hazard ratio for any elevation 
of GGT can be calculated. The given hazard ratios in table 2 and table 3 
were also calculated per 100 units of elevation for illustrating purposes. 
Time-dependent analysis calculates the hazard ratio per 1 IU/L of 
elevated GGT, which in our study was 1.0022. Thus, an elevation of 
100 IU/L would result in 1.0022100 = 1.25 or a 25% increased risk. In 
formula terms a GGT elevation results in a hazard ratio of 1.0022(elevation 
above upper limit in IU/L) for the development of a biliary stricture. 
In clinical practice the calculated hazard ratios of both bile duct dilatation 
on US and the elevation of GGT are multiplied. In our example GGT 
levels 100 IU/L above the reference range together with dilated bile 
ducts on US result in a hazard ratio of 4.3 (3.54 x 1.25), which indicates 
that the risk of developing a biliary stricture requiring intervention in the 
next three months is 4.3 more likely compared to the standard risk. 
It is remarkable that only few studies have addressed the usefulness 
of routinely assessing liver chemistry and performing ultrasound after 
OLT. Hussaini et al.11, for example, showed that US was a valuable tool 
to diagnose biliary strictures with a sensitivity and specificity of 77% 
and 67%, respectively, whereas Zoepfi et al.10 showed no significant 
relationship for both ultrasound and liver enzymes in the detection of 
biliary strictures. Que et al.18 found US to detect biliary strictures with 
a sensitivity and specificity of 90% and 91% respectively, but reported 
GGT and ALP to be of poor diagnostic value even at 10-folds the upper 
limit of normal. However, these studies evaluated liver chemistry using 
sensitivity and specificity in relation to the presence of biliary strictures. 
Although this is a common way to evaluate the diagnostic value of 
clinical tools it has several limitations. Sensitivity and specificity are 
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used to determine the probability an aberrant result in case of present 
disease and vice versa. This method would applicable if the assessment 
of the liver chemistry profile and biliary strictures occur simultaneously 
as is the case in, for example, an emergency setting. However, routine 
assessments are often performed in an outpatient clinic setting where 
most patients have not yet developed symptoms due to biliary strictures. 
Routine assessments are used based on the idea that early detection 
of any aberrance of liver chemistry profile might prompt intervention 
to prevent complications due to biliary strictures such as cholangitis. 
However, the time interval for occurrence of biliary strictures after 
routine assessment of liver chemistry varies for each patient, and the 
time for being at risk varies along. This means that the risk of developing 
a biliary stricture for each patient varies along with the changes in liver 
chemistry. Sensitivity and specificity are also based on dichotomized 
variables, that is: liver chemistry or enzymes are elevated or not. 
However, liver chemistry profiles are continuous variables and change 
over time. These data show that the level of elevation significantly 
impacts the hazard for development of biliary strictures.  
We realize that our study has limitations. We decided to use a follow-
up of one year after OLT, but excluded the first three months. The 
first three months postoperative months were not included because 
early after transplantation liver chemistry levels are influenced by 
many variables, such as ischemia-reperfusion damage, rejection and 
infection. A shorter follow-up would have been possible, but since liver 
chemistry and enzymes levels vary over time it is obligate to assess them 
over a longer period for their utility. A shorter follow-up would have 
weakened the statistical analysis. One might criticize that in this study 
patients were included over a long period of time and management 
of strictures may have changed over the years. Since we focused on 
the development of strictures rather than the treatment, this is not 
a relevant issue in interpreting our findings. Routine liver chemistry 
profiling and abdominal assessments were performed since our center 
started OLTs and strictures and their treatment were consistently 
reported. In a retrospective study such as this, one should be careful 
when using parameters that have not been defined beforehand, such 
as the ultrasound findings. All ultrasound procedures in our institute 
were performed by radiologists with expertise in liver transplantation 
and bile duct dilatation was reported using strict criteria. Other reported 
ultrasound findings of the biliary tree, such as sludge or a thickened 
biliary wall, were not taken into account in our analysis.
The evaluation of routinely assessed liver chemistry and abdominal 
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ultrasound in a time-dependent Cox regression model for predicting 
biliary strictures, as has been used for the first time in the present study, 
takes into account the variability of both changes of liver chemistry 
and bile duct dilatation on US, hence providing clinicians with common 
non-invasive tools for predicting biliary strictures requiring intervention. 
Based on these findings we conclude that routine assessments of 
gamma-glutamyltranspeptidase and abdominal ultrasound are useful for 
early detection of biliary strictures after OLT. We advocate that dilated 
bile ducts on ultrasound and elevated gamma-glutamyltranspeptidase 
more than three months after liver transplantation should prompt 
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Nonanastomotic biliary strictures (NAS) are a serious complica-tion 
after orthotopic liver transplantation (OLT). Matrix metalloproteinases 
(MMPs) are involved in connective tissue remodelling in chronic liver 
disease and complications after OLT. 
Aim
To evaluate the relationship between MMP-2 and MMP-9 gene 
polymorphisms and NAS. 
Methods
MMP-2 ( - 1306 C/T) and MMP-9 ( - 1562 C/T) gene promoter 
polymorphisms were analysed in 314 recipient-donor combinations. 
Serum levels of these MMPs were determined in subgroups of patients 
as well. NAS were identified with various radiological imaging studies 
performed within 4 years after OLT and defined as any stricture, dilation 
or irregularity of the intra- or extrahepatic bile ducts of the liver graft 
followed by an intervention, after exclusion of hepatic artery thrombosis 
and anastomotic strictures. 
Results
The average incidence of NAS was 15%. The major clinical risk factor 
for the development of NAS was PSC in the recipient. The presence 
of the MMP-2 CT genotype in donor and/or recipient was associated 
with a significantly higher incidence of NAS, up to 29% when both 
donor and recipient had the MMP-2 CT genotype (P = 0.003). In the 
multivariate analyses, pre-OLT PSC (hazard ratio 2.1, P = 0.02) and 
MMP-2 CT genotype (hazard ratio 3.5, P = 0.003) were found to be 
independent risk factors for the development of NAS after OLT. No 
obvious association was found between NAS and the MMP-9 genotype 
and serum levels of the MMPs. 
Conclusion
MMP-2 CT genotype of donor and recipient is an independent risk 
factor, in addition to PSC, for the development of NAS after OLT.
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Biliary complications are a common feature after orthotopic liver 
transplantation (OLT), with a reported in-cidence of up to 35%. Leaks 
and strictures are the most common complications, often requiring 
endoscopic, radiological or surgical intervention1-9. Anastomotic strictures 
result from surgical or local ischaemic causes. Main categories of risk 
factors for nonanastomotic biliary strictures (NAS) include ischaemia-
related injury, immunologically induced injury and cytotoxic injury by 
bile salts. A higher incidence of NAS is reported in patients transplanted 
for primary sclerosing cholangitis (PSC) and patients who suffered 
from a postoperative CMV infection10-17. Donation after cardiac death 
(DCD) procedures are also reported to have an increased risk of NAS 
compared with donation after brain death procedures18,19. NAS are often 
referred to as ischae-mic-type biliary lesions, based on the resemblance 
with biliary abnormalities observed after hepatic artery thrombosis. 
The reported incidence of NAS varies in different publications from 1 
to 19%4,5,20-25. If untreated, NAS may lead to cholestasis, severe graft 
dysfunction, septic complications, secondary cirrhosis and graft loss7,23,26.
Matrix metalloproteinases (MMPs) comprise a large family of proteolytic 
enzymes that are important in physiological and disease-related 
extracellular matrix remodelling processes27-30. MMP-2 and MMP-9 
are capable of digesting components of the connective tissue matrix 
and type IV collagen within basement mem-branes. These MMPs are 
considered to play an important role in cancer development, tissue 
remodelling, fibrosis and inflammation, including cirrhosis and liver 
transplantation31-35. We showed previously, for example, that serum 
MMP-2 levels increased, whereas MMP-9 levels decreased in relation 
to the severity of the cirrhosis31. These serum MMP levels were 
subsequently found to change irrespective of their gene polymorphisms 
in late phase injury or rejection (I/R) after liver transplantation36.
The aim of the present study was to assess whether a relationship exists 
between MMP-2 and MMP-9 gene promoter polymorphisms in the 
donor and recipient DNAwith the development of NAS after OLT.
Patients and methods
Patients
All adult patients who received a liver transplant at the Leiden University 
Medical Center (LUMC) and University Medical Center Groningen 
(UMCG) in the Netherlands were eligible for inclusion. For this study, 
202 patients were identified from the transplantation databases who 
underwent OLT at the LUMC between 1992 and 2005, of whom 
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we were able to include 147 patients whose DNAwas available from 
both donor and recipient, and who had at least 7 days of follow-up 
after liver transplantation. Also, patients who received OLT be-tween 
2000 and 2005 at the UMCG were eligible for the study because data 
were available. Of the 224 available patients, 167 unselected patients 
could be included of whom we had DNA from both recipient and 
donor, and who had at least 7 days of follow-up after transplanta-
tion. Genomic DNA was extracted routinely from per-ipheral blood 
and/or tissue samples without given preference to any explicit clinical 
variables. All patients received standard immunosuppressive therapy 
consisting ofcorticosteroids, a calcineurin inhibitor (i.e., cyclospor-ine 
or tacrolimus) with or without mycophenolate mofetil or azathioprine 
and/or basiliximab. Azathioprine was used until 2001, and thereafter 
mycophenolate mofetil was given in case of impaired renal function. 
Demographical and clinicopathological characteristics of the recipient 
at the time of OLT (age, gender, indication for liver transplantation, 
laboratory MELD score), donor information (age, gender and donor 
type), transplanta-tion procedure variables (warm and cold ischaemia 
time) and post-transplant follow-up data of up to 4 years were collected 
from the transplantation databases.
This study was performed with informed consent from the patients 
according to the guidelines of the Medical Ethics Committee of both 
participating centres and in compliance with the Helsinki Declaration.
Nonanastomotic strictures
In this study, only biliary strictures followed that by an intervention were 
included. If a biliary stricture was suspected from clinical findings, liver 
function tests or abdominal ultrasound, further imaging of the biliary 
tract was performed. In both centres, a biliary drain was placed routinely 
after OLT and cholangiography was performed if clinically indicated and 
in the LUMC, cholangiography was also performed routinely 6 weeks 
after OLT. All imaging studies of the biliary tree, performed within 4 
years after OLT, were included [direct cholangiography via the biliary 
drain, percuta-neous transhepatic cholangiodrainage (PTCD), ERCP 
as well as MRCP]. For the purpose of this study, NAS were defined 
as follows: any stricture, dilation or irregularity of the intrahepatic 
or extrahepatic bile ducts of the liver graft, either with or without 
biliary sludge formation, at least 1 cm above the biliary anastomosis 
and treated endoscopically with ERCP and dilation and/or stenting, 
percutaneously with PTCD or by surgical intervention. Hepatic artery 
thrombosis by either Doppler ultrasound or conventional angiography 
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as well as isolated strictures/ stenoses at the bile duct anastomosis and 
related dila-tions were, by definition, excluded from this analysis.
Genotyping
Genomic DNA was extracted by routine methods from peripheral blood 
leucocytes and/or tissue samples. In addition, DNA samples from the 
blood or tissue of the liver donor were obtained from the Eurotransplant 
Reference Laboratory or freshly isolated.
MMP-2: high-resolution DNA melting analysis
MMP2 1306 C/T (rs243865) genotyping, as most relevant SNP, was 
performed with the use of high-resolution DNA melting assay37. 
Sequences of the polymerase chain reaction (PCR) primers were 
5’-CCAGTGCCTC TTGCTGTTTT-3’ (forward) and 5’- GACTTCTGAGC 
TGAGACCTGA-3’ (reverse). The unlabelled probe was designed 
according to the wild-type (C) genotype and had the following 
sequence: 5’-CCACCCAGCACTCCACCTCTTTAGCTC-3’. The probe 
had a 3’-amino-C7 modification to prevent DNA polymerase extension 
during PCR. In brief, high-resolution melting analysis of PCR products 
amplified in the presence of a satu-rating double-stranded DNA dye 
(LCGreenPlus, Idaho Technology, Salt Lake City, Utah, USA) and a 
3’-blocked probe, identified both heterozygous and homozygous 
sequence variants. Heterozygotes were identified by a change in melting 
curve shape, and different homozy-gotes are distinguished by a change 
in melting tempera-ture. In each experiment, sequence-verified control 
donors for each genotype were used.
MMP-9: PCR-RFLP genotyping
The MMP-9 SNP C/T at position - 1562 (rs3918242) was 
determined with PCR analysis followed by restric-tion enzyme 
fragment length polymorphisms (RFLP) analysis, the principles of 
which are described elsewhere36, and confirmed by direct sequence 
analysis of four patients. Briefly, the region flanking the SNP was 
amplified with outer primers 5’-ATGGCTCATGCCCGTAATC-3’ and 
5’-TCACCTTCTTCAAAGCCCTATT-3’ followed by RFLP analysis with 
SphI to produce 352, 35212071145 or 2071145 bp fragments in case 
of CC, CT and TT genotype respectively. Genotypes CC, CT and TT are 
easily identified from the migration pattern on agarose gels36,38-40.
Determination of serological MMP levels
From two subgroups of patients included in our study, we also 
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assessed the serological levels of MMP-2 and MMP-9 before and after 
transplantation. This pretrans-plantation group consisted of 47 patients 
(30 males) with chronic liver disease of various aetiologies, including 27 
patients who eventually underwent an OLT. Their med-ian age was 46 
years (range 16-68). Fourteen patients had chronic viral hepatitis, 14 
patients had cholestatic liver disease, 10 patients had alcohol-related 
liver disease and the remaining nine patients had miscellaneous liver 
diseases. From the group of 27 OLT patients, serum samples 1 month 
after transplantation were evaluated. All serum samples had been 
stored at - 80 °C until use. MMP-2 and MMP-9 concentrations were 
determined using highly specific enzyme-linked immunosorbent assays, 
which measures the pro-enzyme, active- and inhibitor complexed forms, 
as described previously31,36.
Statistical analysis
Data were analysed using spss 17.0 software (SPSS Inc.; Chicago, IL, 
USA). Characteristics of the liver transplant recipients, donors and post-
transplant follow-up data with the risk of developing NAS were analysed 
using the log-rank and two-tailed Student’s t-tests. Differences in the 
serological levels of MMP were analysed using ANOVA.
Genotype frequencies were analysed by generating two-by-three 
contingency tables and statistical analysis was performed using the 
X2-test or the Fisher’s exact test, where appropriate. Comparison of 
time with NAS was made using Kaplan-Meier statistics with a log-rank 
test. Univariate and multivariate analyses were performed using Cox’s 
proportional hazards method. Variables associated with an increased risk 
of NAS at the P <_ 0.15 level in the univariate logistic regression analysis 
were included in the backward stepwise multivariate logistic regression 
model. P-values <_ 0.05 were considered statistically significant.
Results
The study population consisted of 314 OLT donor/ recipient 
combinations of which 48 (15%) developed NAS within the first 4 years 
after transplantation.
MMP-2 genotype and NAS
The frequencies of MMP-2 and MMP-9 gene promoter polymorphisms 
in recipients and in donors vs the occurrence of NAS are given in Table 
1. Evaluation whether the MMP genotype is reflected in the serum 
level indicated that in patients with liver disease no such relation exists. 
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Table 1. Frequencies of matrix metalloproteinase polymorphisms in orthotopic liver 
transplant recipients and donors (n = 314)
Genotype    Recipient    Donor 
    NAS  NoNAS  NAS  No NAS
dbSNP ID SNP   %(n)  %(n)  %(n)  %(n)
MMP-2 — 1306          C → T CC 46 (22)  61 (162)  44 (21)  53 (142)
rs243865   CT 52 (25)  33 (87)  56 (27)  41 (108)
   TT 2 (1)  6 (17)  0 (0)  6 (16)
    P < 0.03, X2 7.2   P = 0.05, X2 5.9 
MMP-9 — 1562           C → T CC 67 (32)  71 (185)  75 (36)  78 (206)
rs3918242   CT 33 (16)  27 (71)  23 (11)  21 (56) 
   TT 0 (0)  2 (5)  2 (1)  1 (2)
    P = 0.46, X2 1.6(n = 309)  P = 0.66, X2 0.9(n = 312)
Table 2. Comparison of donor, recipient and procedure variables between patients with 
and without nonanastomotic biliary strictures after orthotopic liver transplant (n = 314)
   Total  NAS (n = 48)  %  No NAS (n = 266)  %  P-value
Donor variables
Age (in years, median, range)  44 (16–72)  43   (16–67)  44   (9–72)  0.80
Gender
Female    153  29   60  124   47  0.08
Male    161  19   40  142   53
Recipient variables
Age (in years, median, range)  48 (16–70)  45   (16–61)  48   (17–70) 0.08
Gender
Female    122  16   33  106   40  0.39
Male    192  32   67  160   60
Primary liver disease          0.04
Post viral cirrhosis   59  4   8  55   21
Alcoholic cirrhosis   46  5   10  41   15
PSC    57  15   31  42   16
Other cholestatic disease*  28  6   13  22   8
Other disease†   124  18   38  106   40
Laboratory MELD score 
(median, range)   15  15 (6–40)   15 (6–40)    0.98
OLT procedure variables         0.50
DCD    25  5   10  20   8
DBD    289  43   90  246   92
WIT in minutes (mean±SD)  44±13  42±10   44±13    0.37
   n = 296  n = 46   n = 250
CIT in minutes (mean±SD)  573±188  595±183   561±189    0.38
   n = 299  n = 46   n = 253
MMP-2 [rs243865] CT         0.003
No CT present   115  10   21  105   39
CT in recipient or donor  151  24   50  127   48
CT in recipient and donor  48  14   29  34   13
Age, MELD scores, WIT and CIT differences were evaluated by Student’s t-test; frequency distribution data were analysed by w2 
or Fisher’s exact tests, where appropriate.
CIT, cold ischaemia time; time between the start of cold perfusion of graft in the donor and the end of cold preservation of the 
liver graft; DBD, donation after brain death; DCD, donation after cardiac death; MELD, model for end-stage liver disease; MMP, 
matrix metalloproteinase; NAS, nonanastomotic biliary lesions; OLT, orthotopic liver transplantation; PBC, primary biliary cirrhosis; 
PSC, primary sclerosing cholangitis; SD, standard deviation; SSC, secondary sclerosing cholangitis; WIT, warm ischaemia time; 
time between the end of cold ischaemic preservation of the liver graft and portal vein reperfusion in the recipient.
*Other cholestatic disease comprise PBC and SSC.
†Other diseases include predominantly autoimmune hepatitis, cryptogenic cirrhosis and metabolic disorders.
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Specifically, MMP-2 levels in the pre-OLT serum of recipients with a CC  
(n = 32) genotype was 5123 ± 553ng/ml, whereas for those with a CT 
or TT genotype (n = 15), these levels were 5347 ± 886 (NS). For MMP-
9, these levels were 129 ± 16 (n = 36) vs 156 ± 28 (n = 11) respectively 
(NS). The presence of MMP-2 CT genotype in the recipient as well 
as in the donor was significantly associated with the development of 
NAS. Furthermore, the cumulative presence of MMP-2 CT genotype in 
both recipient and donor vs the occurrence ofNAS is shown in Tables 
2 and 3. In the group of patients that developed NAS, the absence of 
a CT genotype was more frequent (21%) than in the patients that did 
not develop NAS (39%) and for CT in donor and recipient, exactly the 
opposite was observed (29% vs 13%, Table 2). If CT genotype was 
present in neither recipient nor donor, the risk of developing NAS was 
9% (10/115). When MMP-2 CT genotype was present in either donor 
or recipient, NAS developed in 16% (24/151) of cases. The occurrence 
of NAS increased to 29% if MMP-2 CT genotype was present in both 
recipient and donor (14/48; P < 0.003, Table 3). Figure 1 shows the 
cumulative incidence ofNAS within 48 months after OLT related to 
the presence of MMP-2 CT genotype in recipient and donor. We also 
evaluated whether this association between genotype MMP-2 and NAS 
was reflected in the serum levels. One month after OLT, the MMP-2 
level in patients with NAS was showed a trend to be lower [i.e., 1892 
± 431ng/ml (n = 5) vs 2869 ± 287 (n = 22), P = 0.06], compared with 
the patients without NAS. Interestingly, a similar trend was observed in 
relation to the MMP-2 genotype, i.e. lower in relation to the presence 
of CT [2969 ± 452 vs 2540 ± 349 vs 2396 ± 448 for no CT in donor or 
recipient (n = 10), CT in donor or recipient (n = 15) and CT in donor and 
recipient ( n  = 2), respectively, NS].
Further assessment of the impact of the MMP-2 genotypes and NAS-
related morbidity by including re-OLTs showed a similar stepwise 
increase in relation to the MMP-2 genotype from 14% (16/115) to 
20% (30/151) and 38% (18/48) respectively (X2 11.66, P = 0.003). 
By including death in the follow-up, this increased to 26% (30/115), 
29% (44/151) and 44% (21/48) respectively (X2 5.18, P = 0.08).
In a similar manner, the MMP-9 genotype distribution of recipient and 
donor vs the occurrence of NAS was evaluated. However, no significant 
correlation was found between MMP-9 genotype and the development 
of NAS (Table 1) or with the serum levels of MMP-9 (data not shown).
Multivariate analysis of MMP-2 genotype and covariates
The development of NAS was significantly higher when PSC was the 
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Table 3. Univariate and multivariate analysis for the association of risk factors of 
nonanastomotic biliary lesions in orthotopic liver transplant patients
     Univariate analysis   Multivariate analysis (n = 299)
Risk factor    NAS  %  HR (95% CI)  P-value  Adjusted HR (95% CI)  P-value
MMP-2 [rs243865] CT       0.01    0.008
Donor and recipient  Vs. none  14/48  29  3.48 (1.55–7.84)  0.003  3.48 (1.54–7.87)  0.003
Donor or recipient  Vs. none  24/151  16  1.84 (0.88–3.84)  0.11  1.64 (0.78–3.46)  0.20
None   Reference  10/115  9  1 (reference)   1 (reference)
Age recipient  Continuous 48/314   0.98 (0.96–1.01)  0.13
Age donor   Continuous 48/314   1.00 (0.98–1.02)  0.72
Gender recipient  Female  16/122  13  0.74 (0.41–1.35)  0.32
  Male  32/192  17  1 (reference)
Gender donor  Female  29/153  19  1.53 (0.86–2.73)  0.15
  Male  19/161  12  1 (reference)
Primary liver disease  PSC  15/57  26  2.0 (1.11–3.76)  0.02  2.14 (1.13–4.06)  0.02
  Other  33/257  13  1 (reference)
Laboratory MELD score Continuous 48/314   1.00 (0.97–1.04)  0.84
Procedure   DCD  5/25  20  1.50 (0.60–3.80)  0.39
  DBD  43/289  15  1 (reference)
CIT   Continuous 46/299   1.000 (1.000–1.002)  0.15  1.001 (1.000–1.003)  0.08
WIT   Continuous 46/296   0.99 (0.96–1.01)  0.38
CI, confidence interval; CIT, cold ischaemia time; time between the start of cold perfusion of graft in the donor and the end 
of cold preservation of the liver graft; DBD, donation after brain death; DCD, donation after cardiac death; HR, hazard ratio; 
MELD, model for end-stage liver disease; MMP, matrix metalloproteinase; NAS, nonanastomotic biliary strictures; OLT, orthotopic 
liver transplantation; PSC, primary sclerosing cholangitis; WIT, warm ischaemia time; time between the end of cold ischaemic 
preservation of the liver graft and portal vein reperfusion in the recipient.
Univariate and backward multivariate analyses were performed using Cox’s proportional hazards method.
Fig. 1. 
Cumulative incidence of NAS within 48 months 
after OLT related to the presence of MMP-2 CT 
genotype in recipient (R) and donor (D). MMP, 
matrix metalloproteinase; NAS, nonanastomotic 
biliary strictures; OLT, orthotopic liver 
transplantation.
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indication for OLT [15/48 cases (31%) vs 33/ 257 cases (13%)], as 
expected. No significant association was found between the occurrence 
of NAS and other transplant characteristics, such as gender and age 
(both of recipient and donor), laboratory MELD score, length of warm 
or cold ischaemia time or DCD procedures. However, it should be noted 
that only 25 DCD procedures were included in this cohort. Also, in 
relation to immunosuppressive therapy, there was no association found 
with the development of NAS, i.e. patients on corticosteroids with a 
calcineurin inhibitor with or without basiliximab had a similar risk of 
developing NAS [13% (27/209) vs 20% (21/105), respectively, NS].
Early ( <_ 12 months) and late (12-48 months) onset of NAS was also 
looked at for all studied risk factors. NAS was diagnosed in 33 cases 
(10.5%) within the first year after OLT and in 15 cases (4.8%) from 
12 to 48 months after OLT. Cold ischaemia time (CIT) was significantly 
longer for the group with early development of NAS (631 ± 179 vs 
520± 174min; P =0.05). Interestingly, the effect of increased CIT and 
the incidence of NAS was particularly present in the first 12 months 
after OLT (hazard ratio 1.002; P =  0.03). Late occurrence of NAS was 
observed relatively more frequently when patients were transplanted for 
PSC. With PSC as the indication for liver transplantation, the occurrence 
of NAS within the first 12 months after OLT was 27% (9/33) as 
opposed to 40% (6/15) from the late onset NAS. A pre-OLT diagnosis 
of PSC was found to be accompanied particu-larly with an increased risk 
of late onset NAS (hazard ratio 3.1; P = 0.03).
Multivariate Cox regression analyses and the backward elimination 
procedure, taking all patient and transplant characteristics into account 
with an increased risk ofNAS (at the level ofP <_ 0.15), indicated that 
the presence of MMP-2 CT genotype in donor and recipient was an 
independent risk factor for the development ofNAS with a higher hazard 
ratio than PSC as primary liver disease (3.5 vs 2.1, respectively; Table 3).
Discussion
In the present study, we report a strong association between the 
presence of MMP-2 CT genotype in donor and/or recipient and the 
development of NAS after OLT. In fact, MMP-2 genotype was a greater 
risk factor for NAS after OLT than PSC. The presence ofthe MMP-2 CT
genotype in donor and/or recipient was found to increase the NAS 
incidence stepwise from 9% when absent, increasing to 16% when 
present in either recipient or donor, further increasing to 29% when 
present in both donor and recipient. In contrast, no association was 
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found between MMP-9 genotype and the development of NAS.
Nonanastomotic strictures are considered to be the most troublesome 
biliary complication after OLT, associated with high retransplant rates 
in up to 20% of patients5,7,25,41. Interestingly, further assessment of 
the impact of the MMP-2 genotypes and NAS-related morbidity in 
our patients, by including re-OLTs, also revealed a stepwise increase 
in relation to the MMP-2 genotype from 14 to 38% and by including 
death in the follow-up, this increased even up from 26 to 44%. 
Apparently, the MMP-2 CT genotype also contributes to the morbidity 
accompanying NAS in the OLT patients.
Various risk factors for NAS have been identified, suggesting a 
multifactorial origin 9,14. The main categories include ischaemia-related 
injury, immune-mediated injury such as ABO compatibility, pre-existing 
disease (especially PSC) and toxic injury by bile salts42,43. In addition to 
clinicopathological factors, we were also interested in the impact of the 
gelatinases MMP-2 and MMP-9 in the development of NAS.
Matrix metalloproteinases comprise a large family of proteolytic 
enzymes involved in physiological and dis-ease-related connective 
tissue remodelling processes and the gelatinases MMP-2 and MMP-9 
are considered to play an important role in inflammation, degradation 
and remodelling processes in the liver29,31,44. MMP activity is regulated 
by various factors and controlled by activation of latent pro-enzymes 
and by interaction with endogenous inhibitors such as tissue inhibitors 
of metal-loproteinases (TIMPs). Recently, several single nucleo-
tide polymorphisms (SNP) in the gene promoter regions of MMPs 
have been found with an impact on the transcription rate (30, 32). 
The C/T transition at posi-tion — 1306 in the promoter ofMMP-2, 
which abolishes the Sp 1 binding site, and leads to decreased mRNA 
transcription and protein expression, is generally ac-cepted to be the 
most relevant SNP for MMP-2. Other SNPs of MMP-2 have been 
reported as well, e.g. — 1575 G/A, — 790 C/T and — 735 C/T, but 
these are in almost complete linkage (dis)equilibrium with — 1306 C/
Tand thus provide no additional information30,32,33. In several studies, 
an association was demonstrated between MMP-2 polymorphisms and 
the development of cancer. It has even been suggested that MMP-2 
represents a potential target for tumour therapeutics32,33.
In the MMP-9 gene, an SNP at position — 1562 is because of a C to T 
substitution in the promoter region. In vitro studies have shown that this 
transition results in loss of binding of a nuclear repression protein and 
increased transcriptional activity in macrophages, associated with the 
severity of coronary atherosclerosis.
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Although other SNPs in the MMP-9 gene have been described, they 
were mainly nonsynonomous located in the exon part of the gene and 
found not to affect the activity or level of the enzyme34,35 In contrast, in 
cardiovascular disease, for example, the — 1562 T allele was found to 
be associated with increased MMP-9 plasma levels35.
In the liver, the hepatic stellate cell seems to be the main cellular source 
ofMMP-2 and when activated these cells are involved in the synthesis 
of matrix proteins and in the regulation of matrix degradation leading 
to liver fibrosis. Following liver injury, the stellate cells become activated 
and can express a wide range of MMPs and TIMPs, but in particular 
MMP-244-46. Increased mRNA expression of MMP-2 was reported in 
liver biopsies of patients with cirrhosis44. We found pre-viously serum 
levels ofMMP-2 to be increased in patients with chronic liver disease 
and strongly correlated with serum markers indicative of a poor liver 
function31. After OLT, a gradual decrease of MMP-2 levels were found 
they remained higher, however, than found in healthy controls and 
increased with recurrent liver dis-ease. MMP-9 is released predominantly 
from neutrophils and macrophages, but the principal source in the 
liver is thought to be the Kupffer cell, the resident macrophage of 
the liver. Taking into account the different hepatic sources of MMP-
2 (parenchymal stellate cells) and MMP-9 (Kupffer cells), one would 
expect a more long-standing effect of MMP-2 polymorphisms compared 
with MMP-9 polymorphisms. This is in line with our findings on the 
development of NAS within 4 years after OLT.
MMP-2 and MMP-9 seem to play a critical role in cold storage 
preservation injury and the reperfusion injury of liver grafts. We found 
previously elevated serum levels of MMP-9 at 1 week after OLT in 
patients with acute allograft rejection45, illustrating that the extracellular 
matrix might be an important target in the process of acute rejection. In 
a recent study, however, we found serum levels to be affected but not in 
association with the MMP-2 and MMP-9 polymorphisms in late phase 
ischaemia/reperfusion I/R after OLT36. Also in the present study, we did 
not find that the genotype of the MMPs was reflected in the respective 
serum level of the patients before OLT. After transplantation, however, 
the MMP-2 levels showed a trend to be lower in patients that developed 
NAS and in association with the — 1306 CT genotype of recipient and 
donor. These observations might indicate a genetically determined 
reduced MMP-2 tissue remodelling as a cause of NAS after OLT, but the 
number of patients evaluated is too low to draw definite conclusions. 
With respect to MMP-9, no genotype ( — 1562 CT)-phenotype (serum 
level) association was found in relation to NAS.
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In the present study, early development of NAS (<_ 12 months) was 
associated with longer cold ischaemia times. It has been well described 
in previous studies that patients who are transplanted for PSC have 
a higher incidence of NAS after transplantation7,20,21,47,48. Our results 
confirm this finding and the multivariate analysis shows PSC to be a risk 
factor for the develop-ment of NAS, independent of MMP-2 genotype 
and occurring late after OLT (Table 3). The multivariate analysis shows 
MMP-2 genotype in donor and recipient to be a much stronger 
predictor for the development of NAS (hazard ratio 3.5) than a pre-OLT 
diagnosis of PSC (hazard ratio 2.1).
In summary, MMP-2 CT genotype in both donor and recipient is 
strongly and independently related to the development of NAS 
within 4 years after OLT. No association was found with MMP-9 CT 
genotype. These observations merit further studies on the influence 
of donor and recipient MMP-2 genotypes and on the MMP-related 
mechanisms involved in the development of NAS after OLT. As NAS 
leads to significant morbidity and graft loss in OLT, MMP-2 gene-
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Chimerism in transplantation medicine refers to the coexistence of cells 
of donor and recipient origin. We used donor/recipient mismatches for 
matrix metalloproteinases (MMP) gene polymorphisms to study the 
presence of chimerism in liver biopsies and in blood after orthotopic liver 
transplantation (OLT).
Methods
MMP-2 and MMP-9 promoter polymorphism donor/recipient 
mismatches were determined in 147 OLT patients. The relationship 
between these MMP polymorphism mismatches in donor and recipient 
DNA with the development of ischemia/reperfusion injury and rejection 
after OLT was evaluated. Liver biopsy specimens and peripheral blood 
samples were subsequently evaluated for the presence of chimerism, 
also in relation to these complications.
Results
MMP polymorphism donor/recipient mismatches were found in 53.7% 
(MMP-2) and 35.5% (MMP-9) of the OLT patients but no relation was 
observed with I/R injury or rejection.
Chimerism in liver biopsy specimens was found to be present in 28.8% 
(MMP-2) and 16.2% (MMP-9) of the cases. Liver chimerism in MMP-2 
was found to be significantly associated with rejection after OLT (Chi-
square 6.4, P=0.01). In addition, evidence of donor chimerism was 
found in peripheral blood samples of the recipients in a few selected 
cases.
Conclusion
Chimerism after liver transplantation can be found in liver biopsy 
specimens and in peripheral blood using MMP polymorphism donor/
recipient mismatches. Liver chimerism in MMP-2 was found to be 
significantly associated with rejection after OLT. The exact clinical and 
functional implications have still to be established.
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Introduction
Chimerism after solid organ transplantation is a fascinating 
phenomenon. In the earliest days of organ transplantation, back in 
the 1960s, Medawar hypothesized that chimerism could lead to graft 
tolerance.1 The existence of chimerism after transplantation have been 
studied by many, but the clinical significance remains unraveled.2-5
Previously, we have addressed different aspects of chimerism within 
the liver, both after orthotopic liver transplantation (OLT) and after 
allogeneic bone marrow transplantation (BMT).6,7 In these earlier studies 
we used in situ hybridization techniques targeting Y-chromosomes. A 
major drawback of this technique is that only a small fraction of sex 
mismatched donor/recipient combinations are relevant to be studied, 
i.e., male recipients receiving a female liver and female recipients 
receiving a male BMT.
In the present study we have used a different technique to investigate 
chimerism after OLT, which allowed us to include a larger number 
of liver transplant recipients. Gene polymorphisms of matrix 
metalloproteinases (MMP) 2 and 9 were analyzed. We previously 
reported on MMP polymorphisms in relation to different complications 
of liver transplantation and found preliminary indications that chimerism 
did occur.8,9 Mismatches between donor and recipients were selected 
to study the presence of chimerism in liver biopsy specimens and in 
peripheral blood after liver transplantation.
The aim of the present study was to further explore the existence of 
chimerism in MMP-2 and MMP-9 promoter polymorphism donor/
recipient mismatches in both liver biopsy specimens and in peripheral 
blood after OLT. The association between these MMP mismatches and 
the clinical occurrence of ischemia/reperfusion injury and rejection after 
OLT was also assessed.
Patients and Methods
Patients
All patients who received a liver transplant at Leiden University Medical 
Center (LUMC) between 1992 and 2005 were eligible for inclusion. 
Of these 202 patients, donor and recipient DNA was available of 147 
patients with at least 7 days of follow-up after OLT. Demographical and 
clinicopathological characteristics of the study population were obtained 
from the transplantation database. 
The study was performed according to the guidelines of the Medical 
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Ethics Committee of the Leiden University Medical Center and in 
compliance with the Helsinki Declaration.
Genotyping
Genomic DNA was extracted by routine methods from peripheral 
blood leukocytes and/or tissue samples. In addition, DNA samples from 
the blood of the liver donors was obtained from the Eurotransplant 
Reference Laboratory or freshy isolated from donor blood or spleen 
tissue. Also, DNA was isolated from liver biopsy tissue of the allograft in 
the recipients, obtained several months (median 17, range 5 to 48) after 
OLT.
MMP-2: high resolution DNA melting analysis
MMP-2 -1306 C/T promoter SNP was determined using a high 
resolution DNA melting assay with the 
5’-CCACCCAGCACTCCACCTCTTTAGCTCF-3’ wild-type (C) gene 
probe, and the primers 5’-CCAGTGCCTCTTGCTGTTTT-3’ (forward) and 
5’-GACTTCTGAG-CTGAGACCTGA-3’ (reverse).9,10  This –1306 C/T 
MMP-2 gene promoter polymorphism was also determined by tetra-
primer amplification refractory mutation system- polymerase chain 
reaction (PCR) analysis, the principles of which are described elsewhere9, 
and confirmed by direct sequence analysis of 4 patients. Briefly, the 
region flanking the SNP was amplified with outer primers 
5’-ACCAGACAAGCCTGAACTTGTCTGA-3’ and 
5’-TGTGACAACCGTCTCTGAGGAATG-3’ together with inner allelic 
specific primers 5’-ATATTCCCCACCCAGCACGCT-3’ and 
5’-GCTGAGACCTGAAGAGCTAAAGAG-TTG-3’. Genotypes CC, CT and 
TT (542+379; 542+379+211; 542+211 bp, respectively) are easily 
identified from the migration pattern on agarose gels.
This common functional polymorphism abolishes an Sp1 binding site 
within the promoter region of MMP-2. In brief, high-resolution melting 
analysis of PCR products amplified in the presence of a saturating 
double-stranded DNA dye (LCGreenPlus, Idaho Technology) and 
the 3’-blocked probe, identifies both heterozygous and homozygous 
sequence variants. Heterozygotes and homozygotes are distinguished 
by differences in the melting curve shape, due to differences in melting 
temperature. In each experiment, sequence-verified control donors for 
each genotype were used.
MMP-2 genotype distribution was as follows: in recipients CC 67.3% 
(n=99), CT 27.9% (n=41), TT 4.8% (n=7) and in donors CC 45.6% 
(n=67), CT 49.7% (n=73), TT 4.8% (n=7).
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MMP-9: PCR-RFLP genotyping
The SNP C/T at position –1562 of the MMP-9 gene promoter 
was determined by PCR-RFLP. The SNP flanking region was 
amplified using primers 5’-ATGGCTCATG-CCCGTAATC-3’ and 
5’-TCACCTTCTTCAAAGCCCTATT-3’ followed by restriction analysis 
with Sph I to produce 352, 352+207+145 or 207+145 bp fragments in 
case of CC, CT and TT genotype, respectively, which are easily identified 
from the migration patterns on agarose gels. 8,11-13
MMP-9 genotype distribution was as follows: in recipients CC 75.9% 
(n=107), CT 23.4% (n=33), TT 0.7% (n=1) and in donors CC 73.0% 
(n=103), CT 27.0% (n=38) and none of the donors had TT genotype.
Assessment of MMP gene mismatch and chimerism in liver biopsy 
specimens and peripheral blood samples
Mismatch in the MMP-2 or -9 genes is defined as a non-identical 
genotype in OLT recipient and donor. Chimerism is defined as the 
presence of an MMP genotype signal in the DNA of the liver biopsy 
after OLT that originates from the recipient and in the blood DNA of the 
recipient after OLT when an MMP genotype signal appears from the 
donor.
Ischemia and reperfusion injury and rejection
The degree of I/R hepatocellular injury was evaluated by measurement 
of aspartate aminotransferase (AST) during the first week after OLT. 
Patients were classified into 2 groups depending on whether the serum 
AST peak was lower than 1,500 IU/L (no or mild I/R injury) or higher 
than 1,500 IU/L (more severe I/R injury), respectively.
Liver biopsies were taken according to our protocol at approximately 1 
week, 3 months, 6 months and one year after OLT, or when there was a 
suspicion of rejection, and then each year. Acute allograft rejection was 
graded according to the Banff scheme. The rejection had to be clinically 
relevant for this study, i.e. histologically confirmed and treated with 
additional immunosuppression.
Statistical Analysis
Genotype frequencies were analyzed by generating two- by-two 
contingency tables. Statistical analysis was performed using the Chi-
square test or Fischer’s Exact test, where appropriate, using SPSS 
software (SPSS Inc; Chicago, IL, USA). Differences were considered to 




Our study population consisted of 147 OLT donor/recipient 
combinations and MMP polymorphism mismatches were found in 
53.7% for MMP-2 (79/147) and in 35.5% for MMP-9 (50/141). 
No statistically significant relation was found between the absence or 
presence of a mismatch at -1306 C/T MMP-2 or -1562 C/T MMP-9 
in relation to the development of I/R injury or rejection after OLT, as 
illustrated in Table 1.
Chimerism in liver biopsy specimens
Of the 79 MMP-2 mismatches, liver biopsy specimens of 59 cases could 
be adequately studied for the presence of chimerism, which was found 
in 28.8% (17/59, Figure 1). For the MMP-9 mismatches, 50 in total, 
liver tissue of 37 patients could reliably be scored for chimerism, which 
was found in 16.2% (6/37).
The presence of chimerism in liver tissue was investigated in relation to 
I/R injury and rejection. A statistically significant association was found 
between chimerism for MMP-2 (but not MMP-9) and the occurrence of 
rejection, i.e., 41.2% versus 11.9% in the patients without chimerism 
(X2=6.4; P=0.01). No association was found with I/R injury and MMP-2 
or MMP-9 (Table 2)
Chimerism in peripheral blood 
To assess chimerism in peripheral blood, donor/recipient combinations 
were selected that consisted of a MMP-2 genotype homozygote 
recipient and either a MMP-2 heterozygote donor or a donor of a 
different homozygote genotype. 27 patients could be included of whom 
blood DNA samples were available 3 to 12 years after OLT. Indications 
of blood chimerism was observed in 18.5% (5/27, Figure 2) of these 
patients, i.e., 6.3% (5/79) of the MMP-2 mismatches and 3.4% (5/147) 
of the total OLT population, where the donor MMP-2 gene signal was 
discernable in the recipient’s blood DNA, in addition to the recipient’s 
own MMP-2 gene signal. MMP-9 chimerism in blood of the recipients 
was not observed.
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Table 1. Mismatch at -1306 C/T MMP-2 or -1562 C/T MMP-9 recipient-donor genotype 





































Table 2. MMP chimerism in liver tissue after OLT in relation to I/R injury and rejection.
Complication
MMP-2 in liver 
biopsy after OLT 
Statistical significance
 

































Chimerism in liver biopsy specimens of OLT 
patients. 
Above: Reference MMP-2 HMRA curves in 
blood: TT in blue, CC in grey and CT in red
Below: Chimeric MMP-2 HMRA curves in 
biopsies. Donor TT and recipient CC in dark 
blue; donor TT and recipient CT in green; donor 
CC and recipient CT in light blue; donor CC and 
recipient TT in red.
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Chimerism in biopsies and blood of OLT 
patients.
Above: MMP-2 HMRA curves of a TT recipient 
and CC donor in dark blue and light blue. Liver 
biopsy chimerism of the patient as shown by the 
CT curve in green. Blood chimerism is indicated 
by the arrow pointing at a minor peak at C in 
the purple TT curve of the recipient.
Below: Blood chimerism in CC recipients with 
CT donors in light blue, with the arrow pointing 
at minor chimeric T peaks; donor CT indicated 
in red, reference TT in green and recipient CC 
in grey.












Assessment of the MMP-2 and MMP-9 genotypes in DNA of OLT 
patients show clear evidence of chimerism, both in liver tissue specimens 
and in peripheral blood, even years after transplantation.
In a previous study we already described liver chimerism in sex-
mismatched donor/recipient mismatches.6 Combinations selected 
were male transplant recipients and female donors in whom cells of 
recipient (male) origin could be readily identified with the use of an 
Y-chromosome specific in-situ hybridization technique.
In addition, patients who received an HLA-mismatched liver transplant 
were studied and chimerism was evaluated using immunohistochemistry 
with HLA class I-specific antibodies. To discriminate between cells of 
recipient and/or donor origin, double staining techniques were used 
with antibodies against specific cell types and subsets, i.e., endothelial 
and bile duct epithelial cells, lymphocytes, monocytes and other 
inflammatory cells. Endothelial cell chimerism was found to be quite 
common, whereas chimerism for biliary epithelial cells and hepatocytes 
could be shown only in a minority of cases. The limitation of using 
Y-chromosomes as a marker of chimerism is that only a small fraction of 
donor/recipient combinations (i.e., female/male) could be included. HLA 
staining could not differentiate hepatocytes from inflammatory cells with 
certainty and another limitation was the (sometimes poor) quality of 
liver biopsy samples for immunohistochemical analysis.
Matrix metalloproteinases are involved in connective tissue remodeling 
processes associated with chronic liver disease and complications 
after OLT.8,14-16  In earlier studies we investigated, for example, MMP 
gene polymorphisms and their relation to ischemia/reperfusion injury, 
rejection and non-anastomotic biliary strictures (NAS) after OLT and 
found the MMP-2 CT genotype to be an independent risk factor for the 
development of NAS.9
Now we specifically studied several single nucleotide polymorphisms 
(SNP) in the gene promotor regions of MMP-2 and MMP-9, that 
were determined in DNA samples of peripheral blood leukocytes and/
or liver tissue samples, for liver chimerism after OLT. For that purpose 
MMP gene mismatches were selected for the assessment of chimerism. 
Using this method we could include a far greater number than with the 
previously used methods (79/147 for MMP-2 and 50/141 for MMP-
9). RFLP and HRMA for MMP-2 polymorphisms gave identical results 
and worked well, whereas for MMP-9 only the RFLP SNP analysis was 
found to be suitable, but this technique was not sensitive enough for 
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blood chimerism. Major advantage of the HRMA technique is that it 
was suitable for analyzing peripheral blood DNA samples of possible 
chimeric post-OLT patients. There are, however, also several limitations. 
The existence of chimerism can only be shown in a qualitative fashion. 
A quantification of chimerism would be very interesting, both in relation 
to donor/recipient and procedure-related variables and complications, 
and the follow-up of chimerism in time after the transplant procedure. 
Another limitation of this HRMA technique is that chimerism in liver 
tissue biopsies cannot be specified for different cell lineages, because 
tissue samples are processed for DNA extraction.
The MMP gene chimerism in liver tissue after OLT was assessed in 
relation to I/R injury and rejection, and an association was found 
between the chimeric MMP-2 genotype, but not for chimeric MMP-9 
due to its low frequency, and the occurrence of rejection. This was not 
unexpected, since acute rejection is characterized by a portal mixed 
inflammatory infiltrate (of recipient origin), in combination with bile duct 
damage and endothelitis. A functional upregulation in acute rejection 
was previously described for MMP-9 and not for MMP-2.16 In the 
present study, however, we analyzed MMP DNA polymorphisms as a 
gene marker and not as a functional MMP parameter. The relation of 
MMP-2 chimeric gene expression and rejection in the post OLT biopsies 
can therefore simply be explained by the influx of a mixed leukocyte 
infiltrate of recipient origin. However, although MMP-2 chimerism in 
the liver biopsies was found to be strongly associated with rejection 
it occurred in only 41.2% of cases where chimerism was observed. 
Nonetheless, in the majority of patients with signs of rejection this 
MMP-2 chimerism was discernable (58.3%; 7 out of 12 rejection cases). 
These observations imply that chimerism per se does not (have to) result 
in rejection. Furthermore, it cannot be excluded that biopsy sampling 
might have affected the chimerism assessment because all patients did 
have a MMP-2 gene mismatch but in 41.7% (5 out of 12 rejection 
cases) no expected chimerism was observed.
Indication of chimerism in peripheral blood samples after OLT was 
found in a minority of patients (18.5% of selected patients, i.e. 6.3% 
MMP-2 mismatches and 3.4% of the total OLT population) where the 
donor MMP-2 gene signal was detected in the recipient’s blood DNA. 
As such an interesting observation was that a liver donor DNA signal 
is discernable in the DNA of circulating blood cells of the recipients. 
Further analyses need to be done in order to evaluate whether this is 
an indication of tolerance and where the signal is coming from, i.e., (re)
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circulating liver (stem)cells or donor (stem)cells that have migrated to 
and recirculate from the recipients bone marrow.   
In conclusion, this study indicates that chimerism after OLT persists 
both within the transplanted liver as well as in peripheral blood. There 
was a relationship between MMP-2 chimerism and rejection. The 
clinical relevance of chimerism in relation to graft tolerance, rejection or 
outcome remains unclear and requires further elucidation.
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Chimerism after orthotopic liver transplantation (OLT) is the main 
focus of the studies described in this thesis. The first study showed that 
chimerism of different cell lineages within the liver graft does occur after 
OLT. Subsequently, in allogeneic blood stem cell recipients, chimerism 
was demonstrated in liver tissue, providing evidence that circulating 
progenitor cells can indeed differentiate into parenchymal liver cells.
The secondary focus of this thesis is on matrix metalloproteinases 
(MMPs). These proteolytic enzymes are involved in a wide variety of 
physiological and disease-related matrix remodeling processes. MMP-
2 and MMP-9 gene promoter polymorphisms were assessed of OLT 
donors and recipients in relation to ischemia/reperfusion injury, acute 
rejection and non-anastomotic biliary strictures after transplantation. 
We performed a side study, in which we evaluated the value of serum 
liver chemistry profile and abdominal ultrasound for detecting clinically 
relevant biliary strictures using time-dependent multivariate regression 
analysis.
The two main themes, chimerism and MMPs, merge in the final 
chapter of this thesis. In liver transplant recipients with donor/recipient 
mismatches for MMP gene polymorphisms chimerism was studied, in 
both liver biopsies as well as peripheral blood after OLT.
Chimerism
Since the early days of organ transplantation the interaction between 
cells of donor and recipient origin has been studied by many in an 
attempt to understand rejection, graft tolerance and graft-versus-
host disease.1-3 Cell migration from the graft to the recipient results in 
systemic chimerism and cell migration from the host to the transplanted 
organ results in intragraft chimerism. Methods used to detect chimeric 
cells in transplanted organs are based on mismatches between donor 
and recipient.4,5
Liver chimerism was evaluated in sex-mismatched donor/recipient 
combinations, as described in chapter 2. This chimerism within the 
transplanted liver was studied after transplantation of a female donor 
liver into a male recipient. Cells of recipient (male) origin were identified 
with the use of a Y-chromosome specific in-situ hybridization technique. 
In the same study HLA-mismatched liver transplants were studied using 
immunohisto-chemistry with HLA class I-specific antibodies. Double 
staining techniques were used with antibodies against specific cell types 
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and subsets to differentiate between different cell lineages. Endothelial 
cell chimerism was found to be quite common. Chimerism for biliary 
epithelial cells and hepatocytes could be shown only in a minority of 
cases. HLA staining was found to be not adequate for differentiating 
hepatocytes from inflammatory cells with certainty. Findings were 
also limited by the (sometimes poor) quality of liver biopsy samples 
for immunohistochemical analysis. From these findings we postulated 
that circulating progenitor cells of recipient origin are probably capable 
of differentiating into endothelial and even epithelial cells within the 
transplanted liver.
In chapter 3 a study is described in which the theory of blood stem 
cells developing into liver cells was further explored. Liver tissue 
specimens were examined from female patients who had received 
allogeneic blood stem cells from a male donor. All patients had been 
diagnosed with a hematologic malignancy, and treated with high-dose 
chemotherapy followed by allogeneic bone marrow transplantation or 
allogeneic peripheral blood stem cell transplantation. Fine-needle liver 
biopsy specimens were obtained because graft-versus-host-disease 
was suspected or from autopsy liver tissue. In this case, Y-chromosome 
identification was used to identify cells of donor origin. For consecutive 
staining an antibody against all known isotypes of the CD45 leucocyte 
common antigen family, present on lymphocytes, monocytes, 
granulocytes, and other inflammatory cells, was used. Y-chromosome-
positive cells, indicating male (donor) origin, were found in all studied 
liver tissue samples. Many of these were likely to be of hematopoietic 
origin, representing infiltrating leukocytes but in some cases, donor-
derived cells clearly appeared to be of non-lymphohematopoietic origin, 
supporting the presence of true tissue chimerism.
Matrix metalloproteinases and transplantation complications
Matrix metalloproteinases are proteolytic enzymes, involved in a wide 
variety of physiopathological tissue matrix remodeling processes.6-9 
We focused on MMP-2 and MMP-9 gene promotor polymorphisms in 
relation to clinical outcome of liver transplantation. Chapter 4 describes 
the relationship of these polymorphisms with ischemia-reperfusion 
damage and rejection after OLT. Serum MMP-2 and MMP-9 levels 
were determined to study potential phenotypical consequences. No 
statistically significant differences between MMP gene promotor 
polymorphisms were found in relation to the development of I/R injury 
and to rejection after liver transplantation. Serum levels of MMP-2 were 
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found to be increased in patients with chronic liver disease and therefore 
a drop of MMP-2 levels was expected after OLT.10,11 This decrease 
was indeed seen, but it occurred independent of the genotype. Serum 
levels of MMP-9 were found to peak at 1 week after OLT, which was 
associated with acute allograft rejection. Irrespective of a genotype 
mismatch between the donor and the recipient we found a comparable 
serum MMP-9 peak and pattern over time.
After liver transplantation the development of biliary strictures is a major 
clinical problem, due to its relatively high frequency, complications, 
morbidity and even mortality.12-15 We were able to assess predictive 
factors of biliary strictures in a large cohort of liver transplant recipients, 
as described in chapter 5. This study focused on routine clinically 
diagnostic tests and their predictive value for the development of bile 
duct strictures, anastomotic as well as non-anastomotic (3 to 12 months 
after OLT). These common tests include liver chemistry profile and 
abdominal ultrasound (US) that are ubiquitously used to assess liver 
transplant recipient. The relationship between these tests and biliary 
complications is obvious, but very little is known on the predictive 
value of sequential profiling of these parameters. 16-18  We performed 
a time-dependent Cox regression analysis to identify predictive 
factors for the development of biliary strictures and found an elevated 
gamma-glutamyltranspeptidase and dilated bile ducts on ultrasound 
to have an independent predictive value for the development of biliary 
strictures requiring intervention. We advocate that dilated bile ducts on 
ultrasound and elevated gamma-glutamyltranspeptidase should prompt 
cholangiography for early diagnosis and therapeutic intervention of 
biliary strictures.
Given the fact that stricture formation in the liver bile ducts is 
accompanied by tissue remodeling and since MMP-2 and MMP-9 are 
considered to play a key role in connective tissue remodeling processes 
in the liver, we decided to study the relation of MMP-2 and 9 gene 
polymorphisms with non-anastomotic biliary strictures (NAS) after liver 
transplantation, as well. Specifically NAS was studied, because these 
strictures are a common and troublesome complication after OLT, 
leading to graft dysfunction, septic complications, secondary cirrhosis 
and even graft loss. The results of this study are described in chapter 6. 
The MMP-2 polymorphism was significantly associated with NAS, and 
donor and recipient genotypes had additive effects. Moreover, primary 
sclerosing cholangitis (PSC) and MMP-2 genotype polymorphism 
were independent risk factors for the development of NAS after OLT. 
No association was found with MMP-9 genotype. A higher risk for 
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developing (late) NAS was recently also described for graft recipients 
carrying specific CCR5 alleles (encoding a chemokine receptor), 
especially in patients transplanted for PSC.19 These and our findings 
strongly suggest that innate pathways contribute to NAS, the etiology 
of which involves multiple other mechanisms, such as ischemia, viral 
infection and bile salt-related injury.15,20
Matrix Metalloproteinase Chimerism 
The last study of this thesis, chapter 7, merged our main focus areas, 
i.e., chimerism and MMPs. Donor/recipient mismatches for MMP 
gene polymorphisms were selected and evidence of chimerism was 
found in liver biopsy specimens for MMP-2 and MMP-9 polymorphism 
mismatches. An association between rejection and a specific MMP-
2 genotype, in donors as well as in recipients, was found, but its role 
in pathophysiology remains to be established. In addition, evidence 
of donor chimerism was found in peripheral blood samples of liver 
transplant recipients in a few selected cases, in accordance with other 
recent studies.21
Discussion
In the chimerism studies described in this thesis a variety of techniques 
was used to study this intriguing phenomenon. Convincing evidence of 
chimerism is found in all three studies, but these studies also illustrate 
the difficulties encountered when studying this phenomenon. The 
selection of donor/recipient combinations depends on the technique 
which is chosen, often cutting down the number of cases that can be 
included (e.g., only the combinations of a female donor and a male 
recipient as in chapter 2). The next challenge was to further identify 
the chimeric cells. Circulating blood cells within the donor liver are 
without question from recipient origin and should be excluded since we 
are interested in true intragraft chimerism. To establish the functional 
relevance of chimerism it is essential to differentiate between different 
cell lineages. With a combination of techniques (determination of 
Y-chromosomes, HLA immunohistochemistry and double staining 
techniques with antibodies against specific cell types) the determination 
of chimeric cells in the liver graft was sometimes possible and at times 
even convincing, but often remained questionable. Poor quality of liver 
tissue samples made this an even more hazardous challenge, especially 
in autopsy specimens (chapter 3).
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Donor/recipient mismatches for MMP gene polymorphisms (chapter 7) 
provided a larger study sample. In this study, MMP gene polymorphisms 
were solely used as a genetic association marker to explore chimerism 
and not as a functional parameter for disease progression as such. The 
disadvantage of this technique is that DNA is extracted from study 
specimens (whole liver tissue or peripheral blood samples), thus making 
differentiation of cell type impossible. However, the larger study sample 
made it possible to study the relation of chimerism in liver tissue to 
clinical outcome variables (I/R injury and rejection) and a statistically 
significant association was found between chimerism for MMP-2 (but 
not MMP-9) and the occurrence of rejection. This observation was 
consistent with earlier studies. However, the limitations in studying 
chimerism after liver transplantations with the described techniques 
are obvious. Indeed, we did find compelling evidence of chimerism, 
but quantification of chimerism could not be assessed and association 
of chimerism to some clinically important variables was difficult, due 
to lack of power. The relationship between the presence of chimerism 
and clinical outcome of organ transplantation thus remains largely 
unresolved. To establish this, we need techniques with a high(er) 
specificity to additionally distinguish between different cell types and 
the possibility to include a much larger cohort of patients for association 
studies with clinical outcome parameters.
Specific MMP-2 and MMP-9 gene promoter polymorphisms 
were studied in relation to clinical outcome parameters after 
liver transplantation. We found a strong association of a specific 
MMP-2 genotype with the development non-anastomotic biliary 
strictures (chapter 6). To assess changes in functional activity of 
MMPs, we studied changes in serum levels in relation to MMP gene 
polymorphisms. Before transplantation, we did not find an association 
between the genotype and the respective serum levels. After 
transplantation, however, MMP-2 levels tended to be lower in patients 
that developed NAS and in association with MMP-2 CT genotype.
MMP-2 levels are increased in patients with chronic liver disease and 
therefore were expected to drop after OLT, as reported previously.10 This 
decrease was indeed observed, but this occurred independent of the 
genotype or a MMP genotypic mismatch between donor and recipient. 
In addition, no association of the MMP polymorphisms and mismatches 
was observed with ischemia/reperfusion or rejection after OLT (chapter 
4).  Similarly, a peak in MMP-9 levels was found after OLT, as previously 




The studies described in this thesis provide compelling evidence of 
chimerism after orthotopic liver transplantation. Cells of recipient 
origin can indeed replace endothelial cells, biliary epithelial cells and 
hepatocytes. After blood stem cell transplantation, donor-derived cells 
can be found in liver tissue specimens. These findings strongly support 
the theory of blood stem cells developing into liver cells of mesenchymal 
origin. We found an association between MMP-2 chimerism and acute 
rejection, but many questions on the clinical relevance of chimerism 
remain unanswered, due to limitations of available techniques. 
Matrix metalloproteinases are important in connective tissue processes 
after liver transplantation. In our liver transplant series, we did not find 
a relationship between MMP genotype polymorphisms and ischemia/
reperfusion damage or rejection after OLT. We did find a strong 
relationship, however, between MMP-2 CT genotype in donor and 
recipient and the development of non-anastomotic biliary strictures. 
In fact, in predicting the development of biliary strictures after OLT, 
we found MMP-2 CT genotype and dilated bile ducts on abdominal 
ultrasound to have a high and comparable hazard ratio. An elevated 
gamma-glutamyltranspeptidase appeared to be a much weaker, but 
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In december 1963 verscheen de eerste publicatie over 
levertransplantatie van dr. Thomas Starzl. Hij beschreef hierin drie 
transplantatieprocedures. Een jongen van 3 jaar oud overleed tijdens 
de operatie door massaal bloedverlies. Twee volwassen mannen 
ondergingen een technisch succesvolle procedure, maar beiden 
overleden binnen enkele weken aan longembolieën.
De eerste levertransplantatie in Nederland werd in 1966 uitgevoerd 
in Leiden, maar de patiënt overleed tijdens de procedure door 
stollingsproblemen. Het duurde nog vele jaren tot levertransplantatie 
een erkende, volwaardige behandeling werd bij zeer ernstig leverfalen. 
Nu worden levertransplantaties in Nederland uitgevoerd in drie centra: 
Groningen (sinds 1979), Rotterdam (sinds 1986) en Leiden (sinds 
1992). Aanvankelijk gingen de meeste zorgen uit naar verbetering 
van chirurgische technieken en het controleren van de bloedstolling. 
Met het verbeteren van de directe overleving werd het controleren 
van de afstotingsreactie belangrijk en inmiddels wordt veel onderzoek 
verricht naar de consequenties van langetermijnoverleving. Ook al is 
de 5-jaarsoverleving inmiddels zo’n 85%, het risico van chirurgische 
complicaties, van afstoting, van galwegcomplicaties en van infecties is 
onverminderd aanwezig.
Chimerisme
Verschillende aspecten van levertransplantatie komen in dit proefschrift 
aan de orde. Het centrale thema is chimerisme. Deze term stamt uit de 
Griekse mythologie, waarin de Chimaera een monsterlijk wezen was 
met het hoofd van een leeuw, het lichaam van een geit en de staart van 
een slang. Meer recent zijn verschillende fantastische chimere wezens 
beschreven in de (tevens verfilmde) boeken van Joanne Kathleen 
Rowling. In de wetenschap spreken we van chimerisme als cellen met 
verschillende genetische achtergronden voorkomen in één individu.
Na transplantatie zijn er twee vormen van chimerisme: ten eerste 
kunnen in het getransplanteerde orgaan cellen van de ontvanger zich 
nestelen en ten tweede kunnen vanuit het transplantaat cellen elders in 
de ontvanger terecht komen.
Over de klinische betekenis van chimerisme wordt al decennialang 
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gespeculeerd. Wanneer in het transplantaat schade ontstaat, 
bijvoorbeeld door ischemie (zuurstoftekort) of afstoting, zou dit door 
de ontvanger gerepareerd kunnen worden, wat leidt tot chimerisme. 
Een tweede hypothese is dat chimerisme kan leiden tot tolerantie voor 
het getransplanteerde orgaan. Meer cellen zijn dan immers afkomstig 
van de ontvanger. Als de ontvanger het orgaan beter tolereert, kan 
wellicht minder medicatie worden gegeven om afstoting tegen te gaan. 
Chimerisme als proces is dus intrigerend en bovendien mogelijk van 
belang voor de klinische praktijk. 
De technieken om chimerisme te bestuderen, berusten op verschillen 
tussen donor en ontvanger. Dit noemen we mismatches. Wanneer 
donor en ontvanger niet hetzelfde geslacht hebben, kan het mannelijke 
Y-chromosoom worden gebruikt om de oorsprong van de cellen vast te 
stellen. De studies die worden beschreven in de hoofdstukken 2 en 3 
zijn op dit principe gebaseerd.
In hoofdstuk 2 hebben we mannelijke ontvangers geselecteerd die een 
lever ontvingen van een vrouwelijke donor. In de getransplanteerde 
lever werd gezocht naar cellen met een Y-chromosoom, afkomstig van 
de ontvanger. Dubbelkleuringen met verschillende antilichamen werden 
gebruikt om vast te stellen wat voor soort cellen dit nu waren. Het ligt 
voor de hand dat circulerende bloedcellen van de ontvanger afkomstig 
zijn, maar het bleek dat ook endotheelcellen, die de bloedvaten 
bekleden, afkomstig kunnen zijn van de ontvanger. Dit was al eerder 
beschreven. Tevens werd gevonden dat galwegepitheel, bekleding 
van de galwegen en zelfs hepatocyten, de levercellen zelf, afkomstig 
kunnen zijn van de ontvanger. Dit kan eigenlijk alleen worden verklaard 
door circulerende stamcellen van de ontvanger, die zich nestelen in de 
getransplanteerde lever en uitgroeien tot verschillende celtypes. In deze 
studie werd dus chimerisme aangetoond na levertransplantatie.
De studie beschreven in hoofdstuk 3 betreft hetzelfde onderwerp, 
maar vanuit een ander perspectief. Nu werd gekeken naar patiënten 
die waren behandeld met een beenmerg-stamceltransplantatie, meestal 
voor een hematologische maligniteit zoals leukemie of een lymfoom. 
Vrouwelijke patiënten werden onderzocht die beenmerg ontvingen van 
een mannelijke donor en bij wie nadien leverweefsel was onderzocht. 
Ook nu werd gekeken naar de aanwezigheid van een Y-chromosoom, 
in dit geval passend bij cellen van donor-origine. In de lever bleken 
inderdaad cellen aantoonbaar afkomstig van de donor. Vaak ging het 
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om verschillende soorten bloedcellen, maar dubbelkleuringen toonden 
aan dat het soms echt om levercellen ging. Zo werd chimerisme 
aangetoond in de lever na beenmerg-stamceltransplantatie.
Matrix metalloproteinasen en complicaties na 
levertransplantatie
Het tweede thema van dit proefschrift, naast chimerisme, betreft matrix 
metalloproteinasen (MMP’s). MMP’s zijn belangrijke enzymen bij de 
opbouw en afbraak van bindweefsel. Ze spelen een rol bij groei en 
wondgenezing, maar ook bijvoorbeeld bij aderverkalking, longemfyseem 
en kwaadaardige ziekten. In de lever werden met name MMP-2 en 
MMP-9 onderzocht. We hebben de genetische variatie, polymorfismen, 
van deze MMP’s bestudeerd in relatie tot verschillende processen na 
levertransplantatie. Ook werd gekeken naar serumspiegels van deze MMP’s.
De studie beschreven in hoofdstuk 4 behandelt de relatie van deze 
MMP’s met afstoting en ischemie-reperfusieschade. Wanneer de 
donorlever enige tijd niet doorbloed is geweest, ontstaat schade door 
zuurstoftekort (ischemie). Het opnieuw doorbloeden van de lever kan 
die schade juist verergeren. Dit proces wordt ischemie-reperfusieschade 
genoemd. Er werd geen duidelijke relatie gevonden tussen genetische 
MMP polymorfismen en afstoting of ischemie-reperfusieschade. Wel 
werd, zoals we na eerdere studies al verwachtten, een daling van de 
MMP-2 en een stijging van MMP-9 spiegels gezien na transplantatie, 
onafhankelijk van het genotype.
In hoofdstuk 6 (hoofdstuk 5 komt later aan de orde) werd opnieuw 
gekeken naar MMP-2 en MMP-9 genetische polymorfismen, maar 
nu in relatie tot galwegstricturen na levertransplantatie. Lekkage van 
gal en galwegvernauwingen (stricturen) zijn de meest voorkomende 
complicaties van de galwegen na levertransplantatie. Ze worden 
onderverdeeld in stricturen bij de aanhechting van de donorgalweg 
met de ontvangergalweg (anastomotische stricturen) en vernauwingen 
op andere plaatsen in de galwegen, de niet-anastomotische stricturen 
(NAS). Deze hebben we bestudeerd en het bleek dat een bepaald 
MMP-2 genotype van zowel de donor als de ontvanger significant 
geassocieerd was met NAS. Naast eerder beschreven oorzaken van 
deze galwegstricturen, zoals ischemie, schade door galzouten, eerdere 
chronische leverziekte of een virusinfectie, blijkt de genetische aanleg 
van donor en ontvanger dus van belang.
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Nu we zoveel informatie hadden verzameld over galwegstricturen (314 
levertransplantaties uit het LUMC-Leiden en het UMCG-Groningen), 
wilden we nagaan of het ontstaan van deze stricturen voorspeld 
kon worden met alledaagse klinische testen. De uitkomsten hiervan 
zijn beschreven in hoofdstuk 5. Leverchemie en echografie van de 
lever worden standaard toegepast na levertransplantatie en er is een 
overduidelijke relatie met de aanwezigheid van galwegstricturen. Maar 
de voorspellende waarde van deze onderzoeken voor het ontstaan van 
galwegstricturen is nauwelijks onderzocht. Een ingewikkeld statistisch 
model, een tijd-afhankelijke Cox  regressie analyse, wees uit dat een 
verhoogd gamma-glutamyltranspeptidase (gamma-GT) en verwijde 
galwegen bij echo-onderzoek een onafhankelijk voorspellende waarde 
hebben voor het ontstaan van galwegstricturen.
Chimerisme en matrix metalloproteinasen
De belangrijke thema’s van dit proefschrift, chimerisme en MMP’s, 
komen samen in hoofdstuk 7. Donor/ontvanger mismatches voor 
MMP polymorfismen werden geselecteerd en chimerisme na 
levertransplantatie kon worden aangetoond in zowel leverweefsel als 
in bloedmonsters. Ook werd een associatie gevonden tussen rejectie en 
MMP-2 chimerisme in de lever. De pathofysiologische betekenis van 
deze associatie is overigens nog onduidelijk.
Conclusie
In de diverse studies van dit proefschrift werd chimerisme overtuigend 
aangetoond. Endotheelcellen, galwegepitheelcellen en levercellen in 
de getransplanteerde lever blijken afkomstig te kunnen zijn van de 
ontvanger. Na beenmerg-stamceltransplantatie kunnen gedifferentieerde 
cellen van de donor gevonden worden in leverweefsel. Maar wat 
is nu de klinische betekenis van dit fenomeen? Decennialang is 
gespeculeerd over een relatie tussen chimerisme en tolerantie voor het 
getransplanteerde orgaan. Om dit te bestuderen is het belangrijk de 
aard en het aantal chimere cellen precies te kunnen bepalen in grote 
groepen patiënten. Het identificeren van chimere cellen bleek soms 
mogelijk, maar soms ook niet, afhankelijk van de gebruikte technieken. 
Het kwantificeren van chimerisme bleek bijzonder lastig. Vaak was maar 
weinig leverweefsel beschikbaar, soms bleek het van matige kwaliteit en 
afhankelijk van de gebruikte techniek kon maar een beperkte selectie 
van donor/ontvanger combinaties worden bestudeerd. Selectie op 
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donor/ontvanger MMP  genotype leverde een relatief groot aantal 
mismatches op, maar met deze techniek was differentiëren naar celtype 
juist weer niet mogelijk. Chimerisme is dus overtuigend aanwezig, maar 
de klinische relevantie blijft vooralsnog onduidelijk.
Matrix metalloproteinasen spelen een belangrijke rol in 
bindweefselprocessen, ook na levertransplantatie. We vonden geen 
relatie tussen MMP polymorfismen en ischemie-reperfusieschade 
of afstoting. Wel vonden we een sterke relatie tussen een specifiek 
MMP-2 genotype, van donor én ontvanger, en niet-anastomotische 
galwegstricturen. Op deze wijze kunnen patiënten worden 
geïdentificeerd die een hoog risico hebben op het ontwikkelingen van 
dit type galwegstricturen.
De voorspellende waarde van routine leverchemie en echografie 
werd onderzocht voor de vroegdetectie van galwegvernauwingen. 
Verwijde galwegen bij lever echografie en een verhoogd gamma-
glutamyltranspeptidase (gamma-GT) bleken een onafhankelijk 
voorspellende waarde te hebben voor het ontstaan van 
deze galwegstricturen. Dit is van belang om deze belangrijke 
galwegcomplicaties vroeg te diagnostiseren en te behandelen.
Concluderend kan worden gesteld dat chimerisme na 
levertransplantatie, zowel vanuit de nieuwe lever als vanuit het 
beenmerg van de ontvanger, overtuigend is aangetoond, maar dat de 
klinische betekenis onopgehelderd blijft. Het sequentieel verrichten van 
lever echografie en het bepalen van gamma-glutamyltranspeptidase 
in serum is van klinische waarde bij het vroegtijdig opsporen van 
galwegstricturen, zodat deze tijdig kunnen worden behandeld. 
Daarnaast heeft het onderzoek naar matrix metalloproteinasen 
aangetoond dat er een duidelijke relatie is van een specifiek MMP-2 
genotype met het ontstaan van galwegstricturen, hetgeen ook kan 
helpen hoog-risicopatiënten te identificeren. Daarnaast zijn er ook 
functionele veranderingen in de MMP spiegels tijdens afstoting en 
ischemie-reperfusieschade na levertransplantie, maar die zijn niet erfelijk 
bepaald.    
115ALAT  Alanine aminotransferase
AML  Acute myelogeneous leukemia
ANED  Alive, no evidence of recurrent disease
AP  Alkaline phosphatase
AS  Anastomotic strictures
AST  Aspartate aminotransferase
CIT  Cold ischemia time
CML  Chronic myelogeneous leukemia
CMV  Cytomegalovirus
CT  Computed tomography
DBD  Donation after brain death
DCD  Donation after cardiac death
DLI  Donor lymphocyte infusion
DNA  Deoxyribonucleic acid
DNED  Deceased, no evidence of recurrent disease
DWED  Deceased with evidence of recurrent disease
ERCP  Endoscopic retrograde cholangiopancreatogram
FISH  Fluorescence in situ hybridization
G-CSF  Granulocyte colony stimulating factor
GGT  Gamma glutamyltranspeptidase
GVHD  Graft versus host disease
HE  Hemotoxylin and eosin
HLA  Human leukocyte antigen




ISH  In situ hybridization
MELD  Model for end-stage liver disease
MM  Multiple myeloma
MMP  Matrix metalloproteinases
MRCP  Magnetic resonance cholangiopancreatogram
NAS  Non-anastomotic strictures
NHL  Non-Hodkgin’s lymphoma
OLT  Orthotopic liver transplantation
PAS  Periodic acid–Schiff
PBC  Primary biliary cirrhosis
PCR  polymerase chain reaction
PSC  Primary sclerosing cholangitis
PSCT  Peripheral blood stem cell transplantation
PTCD  Percutaneous transhepatic cholangiodrainage
RFLP  Restriction fragment length polymorphism
SD  Standard deviation
SNP  Single-nucleotide polymorphism
SSC  Secondary sclerosing cholangitis
TIMP  Tissue inhibitors of metalloproteinases
US  Ultrasonography
WIT  Warm ischemia time
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